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ABSTRACT
STUDY OF THE ENHANCEMENT EFFECT OF CYCLOPENTADECANOLIDE
ON PROTEIN PERMEATION THROUGH LIPID MEMBRANES

By
Zhengmao Li
University of New Hampshire, September 2004

Intranasal drug delivery has been a topic of increasing interest for a
decade as a convenient and reliable method for the systemic administration of
drugs. The low bioavailability of simple formulation of protein drugs, such as
insulin, can be greatly improved by using permeation enhancers. We studied the
effect of cyclopentadecanolide (CPE-215®) as a permeation enhancer in protein
release through lipid bilayer membranes. We successfully designed a novel invitro membrane permeability model using liposomes and performed a series of
transmembrane protein release experiments. These were carried out under a
wide range of conditions in the presence of different permeation enhancer
combinations. The experimental results showed that CPE-215® is an effective
membrane permeation enhancer for proteins and a phase transfer agent, for
example, cyclodextrins, can further enhance the effect of CPE-215®.
Besides the release experiments, studies on insulin solution properties
(self-diffusion and self-association states), the interaction between insulin and

xiii
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liposome and the interaction between CPE-215® and liposomes were carried out.
Based on the mechanistic study and release data, we hypothesized that CPE215® can form transient “pores” in the lipid bilayer that dissolve when CPE-215®
distributes homogeneously within the bilayer and restore the barrier function of
the lipid bilayer. W e performed several experiments that corroborate our
hypothesis.
A mathematical model was developed based on our hypothesized release
mechanism. A semi-empirical nonlinear equation involving four parameters
effectively fits the protein release profiles. The quality of the data fit with this
model is good supporting evidence for the validity of our mechanistic model.
Finally we used a neural network approach to correlate the different release
condition parameters and the four semi-empirical fitting parameters based on our
limited data sets. Reasonable neural networks were formed for the three major
parameters of the mathematical model and provided acceptable prediction
results.

xiv
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CHAPTER 1

INTRODUCTION

Since our research is related to the mucosal delivery of protein/peptide
drugs, an overview of protein/peptide drug delivery is given at the beginning of
this chapter, then the topic is narrowed down to our research - protein transport
though natural membranes with permeation enhancers. Structure and major
components of natural membranes, and different in vitro membrane permeability
models (Caco-2, PAMPA, and liposomes) are discussed. Since liposomes were
selected as our in vitro membrane model, detailed preparation and purification
methods for different kinds of liposomes are presented.

1.1. Objective of Thesis
Cyclopentadecanolide (Figure 1), trademarked as CPE-215® is one
permeation enhancer with proprietary ownership to Bentley Pharmaceuticals, Inc.
Bentley Pharmaceuticals, Inc is using CPE-215® to help protein, peptide, and low
molecular weight therapeutic drugs transport through natural membranes for
delivery to the blood stream. This thesis aims to understand the process behind
the permeation effect of CPE-215®. Pharmaceutical formulations are always
challenged with a need for appropriate animal or human tests. These tests are

1
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typically costly and time consuming, and reproducibility is always difficult. To
effectively develop formulations, it is advantageous to construct in vitro tests to
optimize formulations, before in vivo testing. The goal of this thesis is to establish
an in vitro membrane model for protein transmembrane transport, to understand
the release mechanism of CPE-215®’ and to test intranasal formulations.

Figure 1 Molecular structure of Cyclopentadecanolide (CPE-215®).

1.2. Protein/Peptide Drug Delivery

1.2.1. Proteins and peptides as pharmaceuticals
The use of peptides and proteins for systemic treatment of certain
diseases is now well accepted in medical practice. Peptide/protein drugs are
increasingly becom ing a very im portant class of therapeutical agents as a result

of our gaining more understanding of their role in physiology and pathology as
well as the rapid advances in the field of biotechnology and genetic engineering.

2
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Many of these peptides are endogenous molecules that play an important role in
maintaining organ function and metabolic homeostasis.
Peptide and protein pharmaceuticals are different than conventional low
molecular weight drugs; they are structurally more challenging and complicated;
they are often unstable, have large molecular weights and have charges on the
outer surface. The last two properties lead to poor permeability through biological
membranes and consequently peptides and protein material are difficult to
administer except by injection.1

1.2.2. Protein/Peptide D elivery- A Booming Research Area
There is presently an urgent need to find new ways to deliver peptides and
protein drugs and to control their absorption and distribution in the body. In an
editorial in 1998, Rakesh Jain2 stated that the delivery of therapeutics can be
considered as the next frontier of molecular medicine research. He commented
that extraordinary advances in molecular biology and biotechnology have helped
identify novel targets and develop a vast array of therapeutic agents. However,
(in his view), our understanding of the delivery of therapeutic agents has lagged
behind.
In the past, when developing new products, drug delivery scientists have
often em plo yed delivery strategies to enhan ce a property, such as the controlled

release of the therapeutic agent. However, for the case of peptides and proteins,
drug delivery systems must play a more critical role in enabling a viable product.
In doing so, a detailed knowledge of the properties of the compound needs to be

3
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integrated with delivery technology and the relevant aspects of patho/physiology
and biology.
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Figure 2 Number of published research papers (journal, letter and patent
only) on protein/peptide drug delivery every year from 1985 to 2003.

Usually the number of publications on a research topic shows the
magnitude of people’s interest in the topic. A publication search on
protein/peptide drug delivery using SciFinder Scholar in early 2004, shows that
this is really a booming research area. Figure 2 highlights the number of
published research papers (journal, letter and patent only) on protein/peptide
drug delivery every year from 1985 to 2003. Researchers’ interest in
protein/peptide drug delivery started in the mid 1980s; for the first decade, there

4
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was a steady and slow increase in the number of publications. However, after the
mid 1990s, the number of yearly publications increased drastically, from around
50 a year in 1995 to almost 1300 a year in 2003. There are several key academic
researchers in this booming field, such as Dr. Robert Langer (MIT), Dr. Nicholas
Peppas (U Texas), Dr. Francis Szoka (UCSF), Dr. William Pardridge (UCLA), Dr.
Jacobus Verhoef (Leiden U, Netherlands), Dr. Andreas Bernkop-Schnurch (U
Vienna, Austria), Dr. Allan Hoffman (U Washington), and Dr. Lisbeth Ilium (U
Nottingham, UK), to cite only the most published principal investigators.

1.2.3. Delivery Routes
The choice of delivery routes for drugs is wide (parenteral,3 oral,4,5
pulmonary,67 intranasal,8,9 transdermal,10,11 buccal,12,13 ocular,14,15 rectal,16
vaginal,17 etc.). The clinical application, drug properties, patient convenience, and
required “performance” (e.g. bioavailability), are all key selection factors. The
next sections (1.2.3.1 to 1.2.3.6) are an overview of these delivery routes, recent
development and their pros and cons.

1.2.3.1. Injectable Systems
Injections are inevitably associated with some degree of pain, irrespective
of their route of delivery, whether intramuscular, intravenous, or subcutaneous.
The inherent advantages of injectable systems need to be weighed against their
disadvantages.

5

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

Currently, proteins and peptides are mostly delivered by parenteral
administration. Because they are extremely short-acting, repeated injections are
often required. Parenteral delivery can be used to target compounds to specific
sites (via blood or lymphatic systems), as well as to provide precise
pharmacokinetic and phamacodynamic profiles. Exciting developments have
shown how formulation technologies can be used to provide improved parenteral
delivery (e.g. nanoparticles, liposomes, PEGylation).18,19 Engineering based
systems, such as insulin pumps and injection pen systems (for insulin and
human growth hormone), have gained considerable success in the market.
Needleless injection systems currently under development should have better
patient acceptance.20 These include systems employing liquid or powder
technologies.
Polymer implants and microspheres based on polylactide-coglycolide
(PLGA) have been very successful clinically.21 Flamel Technologies developed a
self-assembled poly-aminoacid nanoparticles system for parenteral delivery of
proteins. However, polymer microspheres are not without problems in terms of
loading, drug stability and release profiles. Processing, particularly sterilization,
remains an issue. New implant systems based on alternative concepts are
currently under investigation including an implantable titanium device.22

1.2.3.2. Oral Delivery
Oral delivery is the most preferred method for the introduction of
therapeutic agents. In 2002, oral delivery technologies accounted for 39% ($14

6
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billion) of the world market ($38 billion).23 This field has been the subject of many
peptide and protein delivery attempts, particularly with insulin; but, as yet, few
oral polypeptide products have reached the market.
Peptides and proteins are inherently unstable in the harsh conditions of
the gastrointestinal tract (pH, enzymes, adsorption to solids); but, even if
instability can be avoided, good absorption is not guaranteed. The work of Drew
et al. on octreotide is instructive.24 Octreotide is a cyclic polypeptide (a
somatostatin analogue) that is very stable even in the small intestines. When
orally given to human as a simple solution, the bioavailability is 0.6%. This can
increase to 3.3% by using a non-ionic surfactant (polyoxyethylene 24-cholesterol
ether). Therefore, for oral administration, it is important to be realistic about
potential product performance. If stability is an issue, then enteric coating and
enzyme inhibitors can be used.25 Absorption can be improved by selecting a
permeation enhancer that can improve transcellular or paracellular transport.
Also of importance is the selection of a preferential absorption site. The small
intestine and large intestine have both advantages and disadvantages.
Therefore, before developing a delivery strategy, it can be important to evaluate
the absorption of a candidate biopharmaceutical. Today it is possible to deliver
drugs into different regions of the human gastrointestinal tract using “smart”
capsules.26 This avoids the highly invasive method of intubation.
Various methods to increase the absorption of challenging molecules from
the gastrointestinal tract have been tried. These include permeation enhancers
such as surfactants, chitosan (and derivatives thereof), chelating agents, as well

7
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as carriers and complexation systems.27 Some of these strategies use known
pharmaceutical excipients (GRAS (Generally Recognized As Safe) status) which
can alter cell permeability, usually by modification of the paracellular pathway.
Non-covalent complexation strategies have also been reported.28 The
modification of peptides and proteins chemically by lipidzation or the attachment
of hydrophilic and hydrophobic polymeric functions has also been described.29,30
Clearly, such modifications result in a new chemical entity and the associated
regulatory issues. The covalent attachment of moieties that permit the
biopharmaceutical to exploit biological transporters is also an active area of
research.31,32 Here again, there is the disadvantage of covalent chemistry, but
these approaches could offer exciting opportunities in the exploitation of natural
pathways. A recent report by Morris et al. could open up new approaches.33 They
found that a 21 residue peptide that had hydrophilic and hydrophobic regions
forms stable non-covalent complexes with peptides and proteins. They were able
to use this system to deliver a model protein into various cell lines. The system
was claimed to have low toxicity but as yet, no in vivo data have been reported.
Alternatively, one may use nanoparticles for the delivery of peptide and
protein drugs into the systemic circulation from the gastrointestinal tract. It is well
known that certain specialized cells (M-cells) in the gastrointestinal tract can take
up and transport particles.34 The size and surface properties of the particles are
key factors. This process is important for the development of oral vaccine
systems. However, the quantities of material transported are low, even with
systems with specific surface markers that provide enhanced interaction between
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particles and cells. Some clinical phase II trials suggested that particle uptake
resulted in less than 0.1% of the administered dose being sequestered.35 This
could be sufficient for a beneficial immune response when developing an oral
vaccine but will surely be of no benefit for the oral delivery of peptides.

1.2.3.3. Pulmonary Delivery
Patton has claimed that the lung is a logical target for non-invasive drug
delivery.36 It should provide rapid onset of action and a variety of delivery devices
(Metered Dose Inhalers (MDI), Dry Powder Inhalers (DPI), nebulizers). Good
absorption, even of polar drugs, can be achieved, if the drug is delivered to the
deep lung. Good patient compliance is to be expected provided that the device
and delivery system are properly engineered. Similarly, good reliability should
also be attainable. Understandably, insulin has been the molecule of choice and
a number of different companies are pursuing novel pulmonary delivery systems
using liquid and powder systems. Reported bioavailabilities, versus s.c.
(subcutaneous) injection, range from 10-20% and reliability would appear to be
as good as or better than for injectable insulin (s.c.). Various products are now in
Phase ll/Phase III clinical evaluation and the results look to be encouraging.
However, some concerns over safety (lung function, cough) and increased
antibody levels h ave been raised recently, but it is likely th at inhaled products for

insulin (and other therapeutic peptides) will reach the market soon. One great
advantage of the lung is that it is possible to obtain reasonable absorption (i.e.
50% of the dose delivered) across the mucosal surfaces of the deep lung-
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alveolar region using simple formulations. Long term effect of pulmonary delivery
has yet to be investigated.

1.2.3.4. Nasal Delivery
The nose is an alternative part of the respiratory system that can be
exploited for the delivery of therapeutic peptides and proteins. Nasal products for
peptide delivery are on the market, but with low bioavailability.37 Nasal delivery
can provide rapid onset of action and good deposition can be achieved readily for
both liquid and powder systems. However, using simple formulations, the
absorption of biopharmaceuticals from the nose of animal models and human is
less than 1%. Therefore, in order to improve reliability and to address cost of
goods issues, absorption enhancers may be required. Various materials have
been studied over the years. While many are effective, most are associated with
problems of irritation and regulatory acceptance.38 Often an increase in
absorption (e.g. bioavailability) is associated with a direct effect of membrane
damage. However, some materials such as certain phospholipids can provide
good absorption with low toxicity; the polysaccharide material chitosan was found
to provide increased drug absorption with no evidence of toxic manifestations.39
The nasal route also provides a unique delivery opportunity. The olfactory
region of the nose can be exploited to provide direct delivery o f drugs into the

brain.40 Recent studies by Frey et al. have demonstrated that polypeptide
materials such as nerve growth factor can reach the CSF and brain tissues 41 In
addition, exciting clinical studies by Fehm and Born42 have demonstrated that
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materials such as arginine vasopressin, angiotensin II, and insulin can be
transported from nose to brain in humans, in low quantities. This could be a novel
way to avoid the blood-brain barrier and to provide a novel means of access to
the brain.

1.2.3.5. Buccal Delivery
The mouth has been examined as a delivery route for biopharmaceuticals
by various groups using animal models and also in humans. The pivotal clinical
studies of de Groot and colleagues using sublingual oxytocin suggest a low
bioavailability of less than 1%.43 Therefore, the results recently reported on the
buccal administration of insulin using a spray device (MDI) are both surprising
and potentially exciting. Reported clinical studies in diabetic subjects have
demonstrated good efficacy with bioavailabilities in the range of 5-10%.44

1.2.3.6. Transdermal Delivery
The transdermal delivery of polypeptides has been evaluated by many
groups, but the results so far are not encouraging.45 Good results in animal
models do not translate well to human (usually because the chosen animal
model has little relevance to the human skin). The skin of human provides a good
barrier. Novel approaches to “driving” polypeptides across the skin, such as
iontophoresis and ultrasound, have been explored but clinical results have been
disappointing 46,47 Insulin is an interesting case where physiological pH is a
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problem when considering iontophoresis. The charge on the molecule changes
with pH gradient across the skin. Under electrophoresis, the molecule can be
forced into the skin; but, as the pH changes from the skin surface to tissue, the
charge on the molecule reverses and the molecule is forced to back out!
A novel transdermal system using “transferosomes" (ultraflexible
liposomes with low pore resistance) has been proposed by Cevc.48 It is claimed
that the system can transport therapeutic amounts of insulin across intact
mammalian skin but detailed clinical results are awaited. Alternative engineering
approaches, such as microneedles produced by photolithography, could well
provide a more reliable transdermal system 49

1.3. Membrane Permeation Enhancers
To minimize the health hazard of repeated injection, there is a need to
search for another systemic delivery route as a non-invasive alternative to
injection. Mucosal delivery routes, such as pulmonary, intranasal and oral routes,
will deliver the drugs through the mucosa and reach the general blood circulation
via numerous capillary vessels present underneath the mucosa.
In mucosal delivery, therapeutic agents need to go through mucous
membranes first; but mucous membranes are not designed to let foreign subjects
go through and into the blood system— on the contrary, one of the critical
functions of the mucus membranes is the barrier function. Some small and
neutral molecules, such as glycerin and vitamins can go through natural
membranes easily. But large molecules, for example protein/peptide drugs,

12

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

cannot go through mucous membranes and into the blood by themselves, in
another words, mucous membranes are not permeable to them. Therefore,
improving the bioavailability of the therapeutic agents is the major task for
protein/peptide mucosal delivery. In order to go through barrier membranes,
protein/peptide drugs need the help of membrane permeation enhancers.
Membrane permeation enhancers are usually small molecules used to
interact with the membranes and increase the permeability of membranes. The
main concerns with membrane permeation enhancers are safety issues: they can
cause irritations and can break the integrity of the membrane. Many molecules
have been studied and used as membrane permeation enhancers. Generally
speaking, permeation enhancers have experienced three generations.50 The first
generation is represented by bile salts and surfactants. The second generation is
represented by salicylates, enamines, fusidate derivatives, acylcarnitines and
phospholipids. Nutrients, hormones and antioxidants form the main force of the
third generation of the membrane permeation enhancers. CPE-215® may fall in
the second generation in this category.

1.4. Membrane Structure
In order to study the permeation property of biological membranes, one
m ust know the structure o f the m em branes. D espite the variab le com positions of

biological membranes, the basic structural unit of virtually all biomembranes is
the phospholipid bilayer, with embedded proteins (Figure 3). This bilayer is a
sheet like structure composed of two layers of phospholipid molecules whose
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polar head groups face the surrounding water and whose fatty acyl chains form a
continuous hydrophobic interior of 4 nm thick. Each phospholipid layer in this
lamellar structure is called a leaflet. The major driving force for the formation of
phospholipid bilayers is hydrophobic interaction between the fatty acyl chains of
glycolipid and phospholipid molecules. Van der Waals interactions among the
hydrocarbon chains favor close packing of these hydrophobic tails. Hydrogen
bonding and electrostatic interactions between the polar head groups and water
molecules also stabilize the bilayer. Therefore, the membrane has a relatively
hydrophilic exterior and a hydrophobic interior.
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Figure 3 Fluid Mosaic Model of biological membrane.51

Membrane proteins are embedded in the lipid bilayer. Some may pass
through the bilayer as transmembrane proteins. Transmembrane proteins are
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amphipathic, which means they have hydrophobic and hydrophilic regions that
are oriented in the same regions in the lipid bilayer. Another name for them is
“integral proteins”. Other types of proteins may be linked only at the cytoplasmic
surface by attachment to a fatty acid chain, or at the external cell surface
attached by an oligosaccharide. In other cases, these non-transmembrane
proteins may be bound to other membrane proteins. Collectively these are called
“peripheral membrane proteins”.
Membrane lipids are numerous and diverse, such as phosphatidylcholine,
phosphatidylserine, sphingomyelin, cholesterol, etc. The lipid components of
biological membranes in animal cells consist predominantly of phospholipids.
The phospholipids have two fatty acyl chains esterified to glycerol and a
hydrophilic “head group”. In animal cells phosphatidylcholine (PC) is the major
phospholipid.
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Figure 4 Molecular structure of some common membrane lipids.

52

Cholesterol is a particular type of lipid. It is a membrane constituent widely
found in biological systems which serves the unique purpose of modulating
membrane fluidity, elasticity, and permeability. It literally fills in the gaps created
by imperfect packing of other lipid species when proteins are embedded in the
membrane. Cholesterol serves much the same purpose in model membranes.
The cholesterol molecule inserts itself in the membrane with the same orientation
as the phospholipid molecules. Figure 5 shows phospholipid molecules with a
cholesterol molecule inserted. Note that the polar head of the cholesterol is
aligned with the polar head of the phospholipids.
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Figure 5 Cholesterol molecules in lipid bilayer.49

Different lipids can have different conformations in water when they gather
together, and those conformations are usually determined by their molecular
shapes (Figure 6). Lipids with a big hydrophilic anionic “head” and a small
hydrophobic hydrocarbon “tail”, for example common detergents, have the shape
of an inverted cone, and will form micelles in water. Lipids with a hydrophilic
“head” and two hydrophobic “tails”, for example most lipids in natural
membranes, have a cylindrical shape, and will form lipid bilayers in water. These
lipid bilayers are thermodynamically stable.
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1.5. In Vitro Membrane Permeability Models
It costs pharmaceutical companies hundreds of millions of dollars to test
drugs in Phase II & III. This makes a compound that demonstrates low
bioavailability during clinical trials unacceptable. To prevent this problem, drug
candidates are screened for their absorption potential early in the discovery and
development phase, when investment in a compound is low, as a filter to remove
poor performers and identify candidates that need to be potentially modified.
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Initially, in silico methods were favored. But computational models based
on molecular properties typically fail when large sets of diverse compounds are
analyzed. This is particularly a problem when conformationally flexible
compounds are used. Membrane retention is also an important phenomenon.
Two compounds can have the same permeability but different membrane
retention characteristics. This retention is often misunderstood or neglected,
which leads to incorrect membrane permeability estimates and calculations. The
failure of physiochemistry-based predictions led to the development of simple
assays to evaluate compound absorption. As a result, two permeability assays
have become prevalent in the past five years: the Caco-2 cell permeability assay
and the parallel artificial membrane permeability assay (PAMPA). These assays
have risen to play important roles in industry, and most companies perform at
least one of them in their research programs.
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Figure 7 Caco-2 and PAMPA. Caco-2 uses compartments of different
volumes separated by a monolayer of cell grown on a filter. PAMPA uses
chambers of the same size, separated by a filter coated with lipid in
organic solvent.
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Liposomes are usually used as model membranes to study the properties
of pure lipids and lipid mixtures. In the drug delivery field, they are mostly used
as drug delivery carriers. However, we found that they can also be used as
membrane permeability models due to their lipid bilayer structure.

1.5.1. Caco-2
First described in the early 1990s, cell permeability studies came to
industry from academia, where several groups worked to develop cell-based
assays that mimicked the passage of drugs through the intestinal mucosa54,55—
the Caco-2 assay was the result.
In typical experiments, a monolayer of cells is grown on a filter separating
two stacked microwell plates. The permeability of compounds through the cells is
determined after the introduction of a drug on one side of the filter. The entire
process has been automated, and when used in conjunction with LC-MS
detection, it enables any compound’s permeability to be determined. It is
recognized by the FDA as one of the few means to measure permeability as part
of the bioequivalence waiver process. Since its introduction, Caco-2 has been
championed as a standard for measuring permeability, but it is not without some
shortcomings.
Caco-2 experiments require up to 20 days for the preparation of stable
monolayers, and the cells must be maintained in protective environments, free
from contamination, and examined for tight-junction formation prior to use. The
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method requires careful sample analysis to calculate permeability correctly.
Interlaboratory variation is a problem because of differences in cell line strains.
Caco-2 cells also contain endogenous transporter and efflux systems, the latter
of which work against the permeability process and can complicate data
interpretation for some compounds. In addition, test compound solubility appears
to be a problem in Caco-2 assays because of the assay conditions.

1.5.2. PAMPA
As a less expensive alternative to Caco-2, Manfred Kansy et al. developed
PAMPA.56 A “PAMPA sandwich” is prepared from two plates that are similar to
those used for traditional Caco-2 experiments (Figure 7). One plate contains a
porous filter disk at the bottom of each well. The other one is a reservoir plate
that is precisely molded to sit under the filter plate so that contact between the
two occurs at the filter. The filter is coated with a solution of lipid material in inert
organic solvent to prepare the artificial membrane. The wells of one plate are
then filled with donor solution (i.e., drug), and the other with acceptor solution
(i.e., buffer); the plates are then stacked to create the sandwich and are
incubated. The drug concentration in the donor and acceptor wells is then
determined by UV or LC-MS methods, and permeability is calculated.57 The
w hole PAMPA process is easily autom ated and com m ercially available.

The lipid choice is flexible and often varies by research group, ranging
from mixtures that reflect the lipid composition of mammalian cell membranes to
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simple synthetic phospholipids.58 Some even forgo the lipid altogether and use
non-polar organic solvents.59
With PAMPA, the emphasis is on simplicity. Because the membrane has
no transporters or efflux systems, only passive permeability is observed. And
because there is no growth period, the analysis can be set up quickly from
standard stock supplies without concern about contamination. This allows
PAMPA to be run without restructuring laboratories to create sterile
environments, making PAMPA experiments easier, faster, and much less
expensive to run than Caco-2 assays.

1.5.3. Liposome
Due to the lack of experience with cell culture and uncertainty with cell
lives, we did not use Caco-2 as the membrane permeability model. As to
PAMPA, its artificial membrane is a filter coated with a solution of lipid materials
in inert organic solvent, which is quite different from the lipid bilayer structure of
biological membranes. In that case, PAMPA will not be a good membrane analog
for us to study the interaction of our hydrophobic permeation enhancer with
biological membranes.
Liposomes have a spherical lipid bilayer structure, which is very similar to
the lipid bilayer structure in biological membranes. Since liposomes can
encapsulate solutions inside and separate the inside solution from the outside,
we found that liposome can be used as a passive membrane permeability model.
By encapsulating the drug solution inside of liposomes and detecting the drug
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concentration in the outside solution, we can monitor the drug transport across
the lipid bilayer.
The research on liposomes is mostly focused on using liposomes as drug
delivery carriers,60,61 and structural model membranes. However, no one has yet
reported using liposomes as passive membrane permeability models before.
More information about liposomes will be introduced in the following
section.

1.6. Liposome as an Artificial Membrane Model
The term “liposome” can be defined as any lipid bilayer structure which
encloses a volume (Figure 8).62,63,64 Many phospholipids, when dispersed in
water, spontaneously form a heterogeneous mixture of vesicular structures which
contain multiple bilayers forming a series of concentric shells.
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Figure 8 Liposome structure (half).65
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There are different kinds of liposomes (vesicles): multilamellar vesicles
(MLV), large unilamellar vesicles (LUV) and small unilamellar vesicles (SUV, <
100 nm in diameter). Practical applications of liposomes have been explored in
three main areas of research, namely in model membrane studies, in controlled
and targeted drug delivery in vivo, and in transfer of genetic and other material
into cells in culture.
One important property of liposome is its thermal phase transition. The
phase transition temperature (Tc) is defined as the temperature required to
induce a change in the lipid physical state from the ordered gel phase, where the
hydrocarbon chains are fully extended and closely packed at low temperature, to
the disordered liquid crystalline phase, where the hydrocarbon chains are
randomly oriented and fluid at more elevated temperature. There are several
factors which directly affect the phase transition temperature including
hydrocarbon length, unsaturation, charge, and headgroup species. As the
hydrocarbon length is increased, van derW aals interactions become stronger
requiring more energy to disrupt the ordered packing, thus the phase transition
temperature increases. Likewise, introducing a double bond into the acyl group
puts a kink in the chain which requires much lower temperatures to induce an
ordered packing arrangement. This property will be the object of a specific study
in Chapter 4.2.
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1.6.1. Preparation of Liposomes
When considering the preparative methodology of liposomes, it has to be
recognized that different applications require different types of liposomes.

1.6.1.1. Multilamellar Vesicles (MLV)
Multilamellar liposomes were first described by Bangham et al.66 The
procedure used by them still remains the simplest and the most widely used. This
involves the deposition of a thin lipid film from an organic solvent medium on the
walls of a container, followed by agitation with an aqueous solution of the
material to be encapsulated. Provided the agitation is carried out at temperatures
above the characteristic gel-liquid crystal phase transition temperature of the
phospholipid and the lipid film is indeed thin, MLV should form spontaneously
with little effort. However, the degree of agitation required to form a good
dispersion of MLV (without poorly hydrated lipid globules) will depend upon the
thickness of the lipid film. With relatively thicker films produced by more
concentrated lipid solutions and/or smaller evaporation vessels, more vigorous
agitation is required.
The MLV appear to be attractive because of the ease of their preparation
and relative stability on storage. However, the disadvantages include low
encapsulation efficiency and inconsistency of properties.
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1.6.1.2. Large Uni- or Oligolamellar Vesicles
Relatively large liposomes with either one or a few lamellae, as for
example the reverse-phase-evaporation vesicles (REV), occupy an intermediate
position between the MLV and small unilamellar vesicles (SUV). Some common
large unilamellar liposome preparation methods will be briefly introduced below.

1.6.1.2.1. Ether Infusion
Ether infusion techniques67,68 can be used to prepare large unilamellar
liposomes. The basic principle is the injection of a solution of lipids in ether into
an aqueous solution of the material to be encapsulated at a temperature high
enough for the rapid evaporation of the solvent. Large molecules such as
proteins and DNA have been encapsulated into liposomes using this technique.
Although the encapsulation efficiency is very low, relatively large aqueous space
volumes have been reported 69 Additionally, the size distribution of the liposomes
is heterogeneous.

1.6.1.2.2. Calcium-Induced Fusion
This method, developed by Papahadjopoulos et al.70 relies on the effect of
calcium ions on acidic phospholipids to form initially cochleate cylindrical
structures, which are then transformed into large unilamellar vesicles (LUV) by
the addition of the chelating agent EDTA. Although the preparative procedure
and efficiency of encapsulation are attractive,71 the presence of calcium ions and
the sequestrant during the formation of the liposomes and consequent
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contamination of the liposomes with these may be unacceptable. Furthermore,
this rather specialized technique is valid only for acidic lipids.

1.6.1.2.3. Reverse-Phase-Evaporation (REV)
This method was introduced by Szoka and Papahadjopoulos72 for the
preparation of large uni- or oligolamellar liposomes incorporating a variety of
drugs and biologically active materials. The efficiency of drug encapsulation,
generally around 50%, is very good. The method appears suitable for use with a
variety of lipids and lipid mixtures and for the encapsulation of even large
macromolecular materials. The aqueous space in these liposomes is 7 to 10
l/mol lipid, which is very high in comparison to MLV and SUV.8 Liposomal
dispersions prepared in this manner are said to be mixtures of large unilamellar
and oligolamellar liposomes with the size and number of lamellae being
dependent upon the nature of the lipid mixture, and possibly the exact
procedure.6,73
The relatively high encapsulation efficiency for a variety of compounds
and the basic principle of going from an emulsion to a liposomal dispersion are
very attractive from scale-up and processing considerations. Greater
reproducibility of liposome size range and drug encapsulation can be expected
due to the a b s e n c e o f the “dry lipid” stage. O n e of the disadvantages of this

method is the need for sonication of the mixture of the lipid solution and the
aqueous drug solution to form an “adequate” emulsion. This step would be
difficult to operate on a large scale in a reproducible manner. Although Szoka
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and Papahadjopoulos6 stressed the need for sonication in order to ensure a
homogeneous emulsion, and thus a primarily unilamellar liposomal dispersion,
other emulsification techniques may be equally effective. Other drawbacks of this
procedure include the presence of the organic solvent in contact with the material
to be encapsulated and the temperature needed for the evaporation of the
solvent under reduced pressure. These conditions may be too severe for
peptides and proteins.

1.6.1.2.4. Rapid Extrusion through Polycarbonate Filter
Lipid extrusion is a technique in which a lipid suspension is forced under
pressure through polycarbonate filters with defined pore sizes to yield particles
with a mean diameter that reflects that of the filter pore.74 Prior to extrusion
through the final pore size, LMV suspensions are disrupted either by several
freeze-thaw cycles or by prefiltering the suspension through a larger pore size.
This method helps prevent the membranes from fouling and improves the
homogeneity of the size distribution of the final suspension. As with all
procedures for downsizing LMV dispersions, the extrusion should be done at a
temperature above the Tc of the lipid. Attempts to extrude below the Tc will be
unsuccessful as the membrane has a tendency to foul with rigid membranes
which cannot pass through the pores.

Preparing liposomes by extrusion allows the size of the liposomes to be
specified by selecting a polycarbonate membrane filters with a specific pore size.
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Mean particle size is quite reproducible from batch to batch. Liposomes made
from extrusion process usually have narrow size distributions.

1.6.1.3. Small Unilamellar Liposomes (SUV)
Small unilamellar liposomes (SUV) are of great interest in drug delivery
because of their potential for controlled drug release in the blood stream and for
targeting to non-reticuloendothelial cells and tissues. The slow clearance of SUV
from circulation after i.v. administration75 offers these possibilities. SUV also have
a potential for fusion with target cell membranes. Methods for the preparation of
SUV are examined in the following sections.

1.6.1.3.1. Sonication
The most widely used procedure for the preparation of SUV consists of
sonicating MLV using either a probe or a sonication bath.76,77 Electron
microscopic techniques are used to visualize the unilamellar structure and to
estimate the size, typically about 50 nm as the mean diameter. In general,
adequate ultrasonic treatment leads to a homogeneous preparation in terms of
size. One of the consequences of the small size of the SUV is the limited
aqueous space inside the liposomes and the low encapsulation efficiency.9
Application of ultrasonic energy as a means of converting MLV to SUV is unlikely
to be a reliable and consistent operation in large-scale manufacture.
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1.6.1.3.2. Ethanol Injection
This procedure, introduced by Batzri and Korn,78 is reported to produce
relatively small unilamellar liposomes. Although this technique is, in principle,
similar to the ether injection method,3 the size and degree of heterogeneity of the
liposomes are dependent upon the concentration of the lipids and the relative
volumes of the alcoholic and the aqueous phases. The basic procedure is
amenable to scale-up and needs to be examined further. Two major drawbacks
of this method are the low drug encapsulation levels and the yield of liposomes
as a very dilute dispersion at the end of the process. An additional concentration
step is required to produce an adequate liposomal dispersion.

1.6.1.3.3. Detergent Dialysis
The detergent dialysis procedure was developed by Milsmann et al.79 In
this method, mixed micelles are first formed by dispersing a phospholipid and a
surfactant in an aqueous solution of the material to be encapsulated. This
dispersion of mixed micelles is then dialyzed extensively, when the surfactant is
gradually removed and the phospholipid assumes a unilamellar liposome
structure. Homogeneous dispersions of SUV are formed by this technique. An
additional advantage is the absence of an evaporation step and elevated
temperatures. This allows encapsulation of labile materials under mild conditions.
The degree of encapsulation is, however, very low because of the loss of
material during dialysis (while the liposomes are being formed), except in the
case of encapsulation of macromolecular compounds. Another disadvantage of

30

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

this method is the presence of considerable amounts of residual surfactant in the
final liposomal dispersion at the end of dialysis.

1.6.1.3.4. Reverse Micelle Method
The reverse micelle method was described in a patent by the Battelle
Memorial Institute.80 In this method, a small quantity of an aqueous solution of
the material to be encapsulated is initially dispersed in a volatile organic solvent
containing the lipid mixture. The inverted micellar dispersion is then redispersed
in an aqueous buffer medium to form a water-in-oil-in-water type emulsion. Upon
evaporation of the solvent under reduced pressure or by means of a stream of
nitrogen, unilamellar liposomes are obtained.
Very high degrees of drug encapsulation, in terms of the encapsulated
drug as a percentage of the total drug used, are claimed. However, it should be
pointed out that the drug solution only forms the interior aqueous phase of the
emulsion. Consequently, the final liposomal dispersion is dilute with respect to
the encapsulated drug, although the apparent degree of encapsulation is high.
This technique has potential for large-scale application and should be explored
further.

1.6.2. Removal of Unbound Drug
When lipophilic drugs of appropriate structure are associated with
liposomes by inclusion in the bilayer phase, the degree of “encapsulation” is
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dependent upon the saturation of the lipid phase. Under these circumstances, it
is possible to achieve degrees of encapsulation of over 90%, making it
unnecessary to remove the unbound drug. However, in the case of water-soluble
drugs, the encapsulated drug is only a fraction of the total drug used. An
additional process step is required to remove the unbound drug from the drugloaded liposomes in dispersion. Dialysis, centrifugation, and gel filtration have
been used for this purpose.

1.6.2.1. Dialysis
Dialysis is probably the simplest and most widely used procedure for the
removal of the unbound drug, except when macromolecular compounds are
involved.81 It is a technique requiring no complicated or expensive equipment and
is capable of being scaled up. Dialysis is effective in removing nearly the entire
free drugs with a sufficient number of changes of the dialyzing medium. Dialysis
is, however, a slow process. Typically, removal of over 95% of the free drug in a
liposomal dispersion might require a minimum of 3 changes of the external
medium over 10 to 24 hr at room temperature. Additionally, the volume of the
liposomal dispersion will alter during dialysis, unless care is taken to balance the
osmotic strengths of the liposomal dispersion and the dialyzing medium. It is also
possible th at the presence of the external dialyzing m edium in equilibrium with

the liposomal dispersion might induce leakage of the encapsulated drug.
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1.6.2.2. Centrifugation
Centrifugation at various g values is an effective means of isolating
various kinds of liposomes from the free drug in the suspending medium.82 Two
or more resuspension and centrifugation steps are usually included to effect a
complete removal of the free drug. The centrifugal force required to pull
liposomes down into a pellet is dependent upon the size of the liposomes, and to
a certain extent, on the flocculation state of the dispersion. The lowest speed
possible to achieve pelleting is best since higher speeds could induce
deformation and/or fusion of liposomes. High g values and conditions of
refrigeration are required for liposomes in the small to medium size ranges.
Clearly, the use of refrigerated centrifuges operating at high speeds with
large volumes of liposomal dispersions is energy intensive and expensive, when
feasible. Therefore, this method may not be suitable for the isolation of small
liposomes. For relatively large liposomes, low speed centrifugation offers the
advantages of a short time scale of operation and an opportunity to concentrate
or dilute the original dispersion to the required extent. It is essential to ensure
that the osmotic strength of the resuspending medium is matched with that of
original liposomal dispersion in order to avoid osmotic shock and rupture of
liposomes.

1.6.2.3. Gel Filtration
Gel permeation chromatographic technique is used extensively both to
separate liposomes from unbound drug and also to fractionate heterogeneous
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liposomal dispersions.83 The technique is very effective and rapid at the
laboratory level. Although gel filtration is used in the purification of biological
materials such as insulin on a large scale, the technique is difficult and
expensive. Additionally, dilution of the liposomal dispersion with the eluting
medium may necessitate another concentration step. Much remains to be
established in regard to recovery levels and lipid losses on the column materials.
Centrifugation is the fastest way to remove unbound drugs from liposomes
among the three; it works fine with large liposomes, but not very well with small
liposomes (<100 nm). Dialysis takes longer time, but it is easier and cheaper
than gel filtration. Gel filtration is a universal method to remove unbound drugs
from liposomes, but it involves gel column packing and may dilute the liposome
suspension after the process.
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CHAPTER 2
METHODOLOGY

In this chapter, the focus is on the design and development of a novel and
valid in vitro membrane release model for protein/peptide drugs. We selected the
kind of lipid that would be used to prepare liposomes and the model proteins, and
determined the protocol for the release experiments. Then improvements on the
liposome preparation, protein detection, and release experiment procedure are
discussed.

2.1. Release Concept “In Vivo” Vs. “In Vitro”
In a conventional intranasal drug delivery configuration, the peptide drug
and the permeation enhancer are formulated together to achieve delivery across
the natural membrane. In our model, we encapsulate the peptide inside the
liposome, and use the formulated permeation enhancer to “free” the peptide from
the liposome. This simple permutation of location is illustrated in Figure 9.
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Figure 9 Contrast between in vivo and in vitro formulation testing.

Indeed, our liposome model differs from the mechanism of in vivo
intranasal delivery. In in vivo intranasal delivery, the peptide drug is in the vicinity
of the permeation enhancer and diffuses into the biological membrane. In the
present liposome model, the peptide is encapsulated inside the liposome, while
the permeation enhancer is added outside. The outside peptide concentration is
measured to quantify the permeation enhancing effect. In both instances the
peptide is required to travel across the membrane. In both situations, the
“assistance” of the permeation enhancer is necessary to achieve faster release
(or permeation) rates. If the peptide release is faster with the addition of a
specific formulation of permeation enhancers, then we know this formulation can
effectively interact with the loaded liposome to let the peptide cross through the
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bilayer. The methodology needed to test the efficiency of a permeation enhancer
formulation is less complex and expensive compared to an in vivo test.

2.2. In Vitro Release Protocol Design
The concept is to encapsulate the protein/peptide drugs inside liposomes,
separate the liposomes from the unencapsulated drugs, then add the permeation
enhancer outside of the liposomes and monitor how fast the encapsulated drugs
can release out of the liposomes. In the following sections, the choice of
liposome lipid, protein and release probes will be discussed.

2.2.1 Liposome
In order to make full use of the lipid, obviously unilamellar liposomes are
more desirable than multilamellar liposomes. During the liposome encapsulation
process of an aqueous solution of drugs, lipids form spherical lipid bilayers and
encapsulate part of the solution inside; after the formation of the liposomes, the
concentrations of the aqueous solutions inside and outside of liposomes are the
same. To increase the liposome encapsulation efficiency, or to encapsulate the
maximum amount of solution with a given amount of lipids, one must answer the
question of how to occupy the maximum total volume with the same total surface
area. The answer to this question is to make one giant unilamellar liposome, but
there is no practical value to make a liposome that big. The practical way to get
high encapsulation efficiency is to make narrow size distribution of large
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unilamellar liposomes, instead of small unilamellar liposomes. W hat size of
unilamellar liposome is appropriate? Due to the structural strength of the lipid
bilayer sphere, it is hard to make large unilamellar liposomes even at the micron
scale. We think unilamellar liposomes with 400 nm in diameter should be both
large enough to reach high encapsulation efficiency, and strong enough to
maintain their shape. Considering the thickness of unilamellar lipid bilayer is
about 5 nm,84 selecting 400 nm as liposome diameter can also reduce the
curvature effect on the permeation study.
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Figure 10 Molecular structure of dipalmitoyl phosphatidylcholine (DPPC).

At first we used only one phospholipid, dipalmitoyl phosphatidylcholine
(DPPC), to prepare the simplest liposome model. Figure 10 shows the molecular
structure of DPPC. DPPC was selected because of its popular usage in liposome
related research and its high concentration and occurrence in natural
membranes.
As seen before, cholesterol is a membrane constituent widely found in
animal systems, which serves a unique purpose of modulating membrane fluidity,
elasticity, and permeability. It literally fills in the gaps created by imperfect
packing of other lipid species when proteins are embedded in the membrane. In
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order to make our liposome model a better analog of natural membrane, later we
made 4:1 (w/w) DPPC: Cholesterol liposomes for the release study.
The total inner aqueous volume ratio

V,

(liters per 1.0 liter of liposome

suspension) of the unilamellar liposomes can be determined by the following
equations. The total number of lipid molecules

Np

was expressed as the function

of the initial concentration of the lipid, C (mole-liter'1),
[2.1]

N p = N 0 -C ,

where

N 0 was

Avogadro’s number. A/j, the number of lipid molecules composing

one unilamellar liposome with radius

r

(A), was expressed as
[2.2]

N , = 4 x ( r 2 + ( r - d ) 2) / S ,

where S and of were the average surface area per lipid molecule in square
angstroms and the thickness of the bilayer membrane in angstrom, respectively.
N,

the number of liposomes with radius r in the solution containing C (mole-liter'1)

lipids, was therefore expressed as
N >- C -s

W =
Nt

,2 .3 ,

4 n ( r 2 + { r - d ) 2)

The total inner aqueous volume ( V) was defined as
[2.4]

V = N - % 7 r ( r - d ) 3 x l 0 ~ 27

In the case of 400 nm unilamellar DPPC liposomes, where C = 3.4 * 10'3
m ole-litter'1 (= 0 .2 5 w t% ), r = 2 0 0 0

A, S = 5 8 A2, and

d = 37

A ,85-86 the total inner

volume was calculated to be 3.8 x 10'2 (liter per 1.0 liter of liposome
suspension), i.e., 3.8% by volume.
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2.2.2 Model Proteins
This project focuses on quantifying the permeation of proteins/peptides
through membranes and characterizing the enhancement effect of CPE-215®.
Insulin (Figure 11) was selected as the protein model for this study because it is
one of the least expensive low molecular weight small proteins available, and
also because it is one of Bentley’s target drugs.

Gin
S«r
Glu J M

A -c h a in

s«<
Thr

Thr)o

B -c h a in

Pro) o
Val

Ala
Glu

Figure 11 The primary structure of human insulin. The black residues
designate the amino acids which are invariant among species of insulin.
The letters indicate the residues involved in association of the molecule.
D, dimer formation. H, hexamer formation.87

Insulin, the hormone that regulates blood glucose levels, is a small protein
(MW 5.8 KDa) comprising two peptide chains connected by disulfide bonds, A
(21 amino acids) and B (30 amino acids). Due to the functional groups on the
chain ends, insulin dissolves in water only at pH below 4.5 and above 7.0. When
insulin concentration is high in solution, with or without the help of zinc, it forms
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dimers or even higher association states, such as tetramers and hexamers.
Monomeric insulin is observed only at low concentration (< 0.1 pM, -0 .6 |jg/ml).87
Bovine serum albumin (BSA) is one of the most widely studied proteins
with a high solubility in water around 5g/100ml. BSA was used as a second
model protein for its higher molecular weight, about 66 KDa, which is about 10
times the molecular weight of insulin.

2.2.3 Release Protocol Flow Chart
The general strategy behind our release studies is illustrated in Figure 12.
We first prepared an insulin buffer solution, and then used the extrusion method
to prepare narrow size distribution large unilamellar liposomes to encapsulate
some of the insulin solution inside, and then separated the liposomes from the
unencapsulated insulin with a gel filtration column at 4 °C. Then liposomes were
collected for the release study. After adding the permeation enhancer
formulation, the liposome solution was held at 37 °C, and small amount of
liposome samples were periodically taken out and released insulin was
separated from liposomes. Finally we measured the insulin concentration outside
the liposomes.
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Figure 12 In vitro release protocol design.

2.3. Drug Modification
Although insulin is one of the smallest proteins, it is still a large molecule
compared to lipids. The lipid DPPC has a molecular weight of only 734 Da, while
insulin in monomeric form has more than 50 amino acids with a molecular weight
near 6000 Da, not taking into account the insulin that may be present in the
hexameric form. There is an equilibrium between insulin monomers, dimers and
tetramers (possibly hexamers) in solution. Since small and neutral molecules,
such as water, glycerol and vitamins, can go through biological membranes fairly
easy, at first we suspected the protein membrane permeation process is size and
charge controlled. We assumed that the smaller the protein, the easier it could
go through the lipid bilayer. In that case, we would like to use the lower
association states of insulin, such as monomers or dimers, to do the release
experiments, then we need very dilute insulin solution (insulin monomer
concentration limit is 0.1 pM, ~0.6 pg/ml)87.
Such very dilute insulin concentrations make detecting insulin a challenge
in itself. The UV technique is not sensitive enough at such low concentration.
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Fluorescence is much more sensitive, and insulin has intrinsic fluorescence
signal due to its tyrosine and phenylalanine amino acid residues, but that is not a
strong fluorescence signal.
To improve the detection sensitivity of insulin molecule, we decided to
attach a fluorescent label to insulin. Amine-reactive reagents may be conjugated
with virtually any protein or peptide. After consideration of many possibilities, an
amine-reactive fluorescent analog, fluorescein-5-isothiocyanate (Figure 13), was
selected because it has a relatively high

smax

(7 7 ,0 0 0 at pH 9 ) with a relatively

low price. The isothiocyanate group reacts with basic amine groups at high pH
and forms a covalent bond to derivatize the protein. Besides the two amine
groups at the two N-terminals, insulin has two basic amine groups from the side
chains of lysine and arginine; therefore, there should be no more than 4
fluorescence probes on each insulin molecule after the labeling reaction. The
labeling reaction is done in a mild condition: mix the insulin in a pH 9 bicarbonate
buffered solution using dimethyl formamide (DMF) as a solvent with the reagents
and stir at room temperature for an hour. Excess reagent is used to react with
insulin, and labeled insulin can be easily separated using a gel filtration column.
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Figure 13 Molecular structure of the fluorescent probe, fluorescein-5isothiocyanate.

Based on the manufacturer’s data, the derivative has an excitation and
emission wavelength of 494 nm and 518 nm respectively. In practice, in the SLM
AMINCO Bowman® Series 2 luminescence spectrometer, the maximum
excitation and emission wavelengths are 492 nm and 516 nm respectively. After
the labeling, the detection limits were determined to be 1 ng/ml_.
Although the labeling conditions were mild, there was some concern
whether the process breaks the bonds within protein, especially the disulfide
bonds. Obviously we do not want to see protein degradation due to the
fluorescence labeling process. We use the aqueous GPC (Gel Permeation
Chromatography) with the Wyatt® light scattering detector (DAWN EOS) and
refractive index detector to compare the protein samples before and after the
labeling process to see if there is a decrease of protein molecular weight after the
labeling.
When a polarized, monochromatic laser beam passes through a solvent
containing proteins, the light scattered by the molecules at an angle to the
incident beam over the light scattered by the solvent alone is directly proportional
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to the molecular weight multiplied by the concentration of the molecule. This
characteristic of static light scattering is used for determining the absolute
molecular weight of eluting biomolecules.88 Therefore, light scattering is not very
sensitive to low molecular weight proteins. Since the molecular weight of insulin
is small (less than 6 KDa), we used BSA (MW 66 KDa) instead to test the
potential degradation effect of the labeling process. Since proteins with higher
molecular weight are more complicated and more sensitive to outer environment
changes, using BSA to test the labeling process is conceptually more relevant.
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Figure 14 Aqueous GPC trace of 4.3 mg/ml BSA, eluant 100 mM KCI 10
mM BTP pH 6.5 buffer. The upper trace is from the 90° angle light
scattering detector, the lower trace is from the refractive index detector.
Four interesting peaks in the right 90° angle light scattering trace were
selected and the average molecular weights of each peak were given out.
The GPC column was TSK G3000SWXL column.
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Figure 15 Aqueous GPC trace of 4 mg/ml tagged BSA, eluant 100 mM
KC110 mM BTP pH 6.5 buffer. The upper trace is from the 90° angle light
scattering detector, the lower trace is from the refractive index detector.
Four interesting peaks in the right 90° angle light scattering trace were
selected and the average molecular weights of each peak were given out.
The GPC column was TSK G3000SWXL column.
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Figure 14 and 15 show the aqueous GPC traces of BSA before and after
the fluorescence labeling process. In each figure, the upper left trace is from the
90° angle light scattering detector, and the lower left trace is from the refractive
index detector; the right one is the enlarged trace from the 90° angle light
scattering detector, four interesting peaks on the trace were selected, and the
average molecular weights for each peak were computed. In Figure 14 and 15,
the light scattering traces of tagged BSA and original BSA are almost identical, in
number of peaks, peak positions and peak shapes. In both figures, peak #1 (from
4.2 min to 4.7 min) is a tiny bump, the major peaks are peak #2 (from 5.0 min to
5.7 min) and peak #3 (from 5.9 min to 6.5 min), peak #4 (from 7.6 min to 8.1 min)
is also a tiny bump in the light scattering traces. The peak after 9 min in the
refractive index trace is the solvent peak -- the original solvent for the BSA
sample came out. Because light scattering is more sensitive to bigger
molecules/particles, while refractive index detector only focuses on
concentrations, the relative peak area of BSA dimer/trimer (peak #2) comparing
to BSA monomer (peak #3) is bigger in the trace of light scattering detector than
in the trace of refractive index detector.
From the peak position and the average molecular weight given by the
program, peak #3 is identified as the BSA monomer peak, and peak #2 as the
peak for the higher association state of BSA. In Figure 14, the molecular weight
of original BSA monomer given by the Wyatt® program is 80 KDa, which is a little
more than the real number (66 KDa) and may be due to some incorrect
parameters in the program. Actually the relative numbers are more important to
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us. The molecular weight of higher association state BSA given by the program is
about 220 KDa, which is about 2.75 times the molecular weight of monomer and
means that is the mixture of BSA dimers and trimers. In Figure 15, the molecular
weight of tagged BSA monomer is about 91 KDa, which is more than that of the
original BSA monomer and means some fluorescent probes have attached to
BSA. The molecular weight of higher association state tagged BSA given by the
program is about 230 KDa, which means attached fluorescent probes did not
affect the self-association of BSA, tagged BSA can still have higher association
states and that is still a mixture of dimers and trimers of tagged BSA.
Every peak in Figure 15 can find its corresponding peak in Figure 14 at
almost the same retention time and with almost the same shape, and there is no
additional low molecular weight peak appearing in Figure 15 that would indicate
BSA degradation by the labeling process. Based on the analysis, this fluorescent
probe labeling process is efficient and safe for proteins, no protein degradation is
detected after the process and the fluorescence tagged proteins still have self
association ability.
Since a fluorescence signal was used to monitor the insulin release, it was
necessary to determine the relationship between the fluorescence signal and
tagged insulin concentration; the fluorescence stability of the tagged insulin is
also important for long term release studies. Fluorescence measurements of
different tagged insulin concentrations at pH 7 in phosphate buffer were carried
out. Figure 16 shows the calibration curve of fluorescence signal verse insulin
concentration. The data indicate a linear relationship between the fluorescence
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signal and concentration. In order to make sure of the fluorescence long-term
stability, we stored the tagged insulin solutions with different concentrations at 4
°C and performed fluorescence signal measurement over 90 days. The result
(Figure 16) showed the fluorescence signal was stable for at least 90 days.
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Figure 16 Tagged insulin fluorescence calibration and stability data at pH
7 in phosphate buffer.

2.4. Liposome Synthesis and Size Measurement
T h e extrusion m ethod can prepare desired size liposom es with relatively

narrow size distribution by extruding lipid suspension through a fixed pore size
polycarbonate membrane filter at a temperature higher than the transition
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temperature of the lipid. Due to obvious advantages over other liposome
preparation methods, we chose the extrusion method to prepare liposomes.
The working mechanism of a liposome extruder is not complicated as it
only needs a high pressure system, a sample reservoir, a filter holder and a
temperature control. Figure 17 shows the design of my custom-made liposome
extruder. Valve 1 is a three-way valve, it can connect either A or B to C, or totally
closed. Valve 2 is identical to Valve 1, and it can let DE or DF be connected, or
close the lines between DE and DF. A is connected to a nitrogen gas cylinder to
provide high pressure for the extrusion. B is used to add liposome samples to the
sample reservoir loop. E is used to release the high pressure inside the sample
reservoir loop after the extrusion making the sample loading/reloading from B
possible (without DE open to air, it is impossible to load/reload liposome samples
to the reservoir loop from B). The components within the dashed line are
submerged in a water bath when the extrusion process begins. The membrane
filter is hydrated before it is placed inside the membrane holder. When loading
the liposome samples, Valve 1 and 2 are adjusted so that B, C, D, E are
connected. A syringe is used to load the raw liposomes from B to the reservoir
loop. After the loading, Valve 1 and 2 are adjusted so that A, C, D, F, G are
connected, then the reservoir loop and membrane filter holder are submerged in
the water bath, then the gas pressure is established to start the extrusion.
Multiple extrusions are needed to make narrow size distribution liposomes, so
the liposomes need to be reloaded in the reservoir loop after each extrusion.
After the extrusion is performed, the high pressure gas inlet is closed, and the
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extruder is removed from the water bath. Valve 2 is turned to connect DE and
release the remaining pressure inside of the sample reservoir loop. Then Valve 1
is turned to connect BC and the liposomes are loaded for the next extrusion.
Since the phase transition temperature of DPPC is 41 °C and the water
bath temperature should be higher than the lipid phase transition temperature,
we selected 50 °C as the water bath temperature.

1
High pressure inlet ------- ——

----- —— Add sample

Sample reservoir loop
D
Water bath
Open to air

J

Membrane filter holder

G

Collect liposome

Figure 17 Block diagram of the custom-made liposome extruder. Valve 1
is a three-way valve, it can either let AC connected or BC connected, or
totally close the lines of AC and BC. Valve 2 is the same as Valve 1, and it
can let DE or DF connected, or close the lines of DE and DF. A is
connected to a nitrogen gas cylinder to provide high pressure for the

extrusion. B is used to add liposome samples to the sample reservoir
loop. E is used to release the high pressure inside the sample reservoir
loop after the extrusion and make the sample loading/reloading from B
possible. The components within the dashed line will be submerged in the
water bath when the extrusion process begins.
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Figure 18 Custom-made liposome extruder (without showing the water bath
and high pressure gas inlet).

W e chose a 400 nm pore size polycarbonate membrane filters to make
large unilamellar liposomes. The thickness of one lipid bilayer is about 5 nm, and
using 400 nm diameter large unilamellar liposome can greatly reduce the
curvature effect of the liposome, so that the liposome leakage profile is similar to
that of a planar lipid bilayer.
We used a light scattering instrument (Microtrac S3000) to measure the
liposome size and distribution after extrusion. Figure 19 shows one example of
DPPC liposome size distribution after extrusion through a 400 nm membrane
filter. This shows an essentially monodispersed distribution: volume-average
diameter 354 nm, area-average diameter 351 nm, number-average diameter 345
nm.
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Figure 19 DPPC liposome size distribution measured by Microtrac S3000
after extrusion through a 400 nm polycarbonate membrane filter. This
shows a very narrow distribution: volume-average diameter 354 nm, areaaverage diameter 351 nm, number-average diameter 345 nm.

2.5. Permeation Enhancer Combinations
CPE-215® is the permeation enhancer Bentley uses for the intranasal
emulsion formulations, but its melting point makes a problem for emulsion
formulation. CPE-215® has a melting point of 34 °C, which makes it a solid at
room temperature. Figure 20 shows the thermal property of CPE-215® by
Differential Scanning Calorimeter (Q100 series modulated DSC from TA
Instrument, Inc). In Figure 20, CPE-215® was equilibrated at -20 °C first, then
heated at 3 °C /min to 100 °C, and then cooled at 3 °C /min back to -20 °C. The
top trace shows the cooling process, and the large exothermal peak indicates
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crystallization which starts at 33.5 °C. The bottom trace shows the heating
process, and the large endothermal peak indicates melting process which starts
at 34 °C. In order to make a practical formulation, we need to be sure that CPE215® will not crystallize at storage temperature and while in use.
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Figure 20 DSC trace of CPE-215® (exo up). The sample was equilibrated
at -20 °C first, then heated at 3 °C/min to 100 °C, and then cooled at 3 °C
/min back to -20 °C. The top trace shows the cooling process, and the
large exothermal peak indicates crystallization. The bottom trace shows
the heating process, and the large endothermal peak indicates melting
process.

W e tried to use different additives, such as sesame oil, cottonseed oil, and
soybean oil, to lower the melting temperature of CPE-215®, and found that
cottonseed oil could successfully lower the melting and crystalline temperature of
CPE-215®. Figure 21 shows the thermal property of 3:1 (w/w) CPE-215®:
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cottonseed oil by DSC (Q100 series modulated DSC from TA Instrument, Inc). In
Figure 21, the mixture was equilibrated at -20 °C first, then heated at 3 °C /min to
100 °C, and then cooled at 3 °C /min back to -20 °C. The top trace shows the
cooling process, and the crystallization peak shows that the mixture does not
crystallize until cooled to 5 °C. The bottom trace shows the heating process, it is
hard to identify the exact temperature at which the mixture starts to melt, but it
appears around 5 °C. The mixture only has one melting/crystalline peak at much
lower temperature compared to pure CPE-215®, which shows complete
miscibility between CPE-215® and cottonseed oil. In our study, all the CPE215®/cottonseed oil mixture we used were 3:1 (w/w) oil mixtures.
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Figure 21 DSC trace of 3:1 (w/w) CPE-215®: Cottonseed oil. The sample
was equilibrated at -20 °C first, then heated at 3 °C/min to 100 °C, and
then cooled at 3 °C /min back to -20 °C. The top trace shows the cooling
process, and the large exothermal peak indicates crystallization. The
bottom trace shows the heating process, and the large endothermal peak
indicates melting process.

2.6. Liposome Cleaning
After the extrusion, narrow size distribution large unilamellar liposomes
are made, but there are insulin molecules remaining both inside and outside of
the liposomes. Separating the outside free insulin molecules from the liposomes
is the last step before release studies.
At first we used gel filtration to separate the outside insulin from
liposomes. However, after we collected the liposomes by gel filtration and
preformed the insulin release experiment, at the beginning of the release
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experiment, the fluorescence signals of free insulin in solution at time “zero” were
much higher than we expected. We assumed it could be due to the adsorption of
insulin on the outside surface of the liposomes. During the gel filtration, the
adsorbed insulin eluted with the liposomes; after gel filtration, the outside insulin
concentration was so low that the adsorbed insulin desorbed from the liposomes
and went into the solution, which produced the high fluorescence signal at the
starting points. Further gel filtrations might be a way to solve that problem, but
that could also further dilute the liposome suspension, and the gel filtration
process involved more labor and time.
Since it was found that our liposomes had a slightly higher density than
water, a centrifuge technique was studied to make the outside of liposomes
“insulin free”. For this to be accomplished, the liposome suspension after
extrusion was centrifuged at 650 g at 4 °C for 30 minutes, then the supernatant
was taken out and fresh buffer was added; then the same procedure was
repeated. This may be called centrifugal extraction, which is similar to dialysis but
faster and does not require a membrane.
After each cycle of centrifugal extraction, some clear supernatant was
taken out for fluorescence measurement to detect the free insulin concentration
in the supernatant. Figure 22 shows the result of the measurement and the effect
of centrifugal extraction on the free insulin concentration outside of the
liposomes. After 10 cycles of centrifugal extraction, the requirement of
“substantially insulin free” outside the liposome could be reached.
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Figure 22 Effect of centrifugal extraction on the concentration of free
insulin outside of the liposomes.

During the insulin release experiment, after taking out the liposome
samples from the release tubes and before the fluorescence measurement for
the released insulin concentration, free insulin molecules outside need to be
separated from liposomes again. This time the outside insulin is what we need
and the insulin concentration should not be changed after the separation.
Therefore, this time we used centrifugal filtration.
The process of centrifugal filtration uses semi-permeable membrane filters
and centrifugal force to separate molecular species on the basis of size and
shape. T h e disposable centrifugal units consist o f a sam ple filter unit and a

filtration collection tube. A sample is loaded in the filter unit that is then put into
the collection tube. Together the filter unit and collection tube are put in a
centrifuge and spun at the appropriate speed. Since the size of our liposomes is
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around 400 nm in diameter and the size of hexamer insulin is less than 10 nm in
diameter, a membrane filter with the nominal molecular weight limits (NMWL) of
50 KDa can retain the liposomes and let insulin molecules go through without
any problems. However, liposomes do not have a solid surface, therefore, the
centrifuge conditions need to be adjusted to make sure the liposomes will not
break during the process of centrifugal filtration. W e did a test by performing the
centrifugal filtration at different speed at 4 °C with 400 nm DPPC liposomes and
found that filtration at 500 g not only did not break the liposomes, but also
provided reasonable separation times. Another concern is that too many
liposomes might clog the filter membrane. To solve this problem, before placing
the liposomes into the sample filter unit, we centrifuge them at 500 g at 4 °C for
20 minutes and only take the supernatant to perform the centrifugal filtration
process. In this case, fewer liposomes have a chance to contact the filter
membrane.

2.7. Drug Release with Shaker Table
Once we obtain “clean” liposomes with insulin solution inside, we can start
the release experiments. In order to keep the liposome samples at controlled
temperature, we use 15ml centrifuge tubes to contain the liposome samples and
fit the tubes in the necks of the three-neck jacketed flasks, which are connected
to a temperature controlled water bath (Figure 23). Both the inside and jacketed
flasks are filled with water; in this case the temperature inside the flask is
controlled by the water bath, and the sample temperature is controlled by the
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water inside of the flask. W e found that once they reached temperature
equilibrium, there was almost no temperature difference between water bath and
liposome samples. A shaker table is used to give gentle shaking to the liposome
samples so that there is no concentration gradient in each tube to affect the
insulin release.

Figure 23 Protein release experiment setup. The release liposome
samples are in the red-capped centrifuge tubes. The tubes are inserted in
the necks of the three-neck jacketed flasks, and the flasks are used as
water baths to control the sample temperature. The shaker table is used
to give gentle steering to the liposome samples.
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2.8. Animal Test Validation
All the experiments we designed and performed were membrane
permeation in vitro tests, and needed in vivo animal tests to validate the model. If
the in vitro test results were significantly different from those of the in vivo animal
tests, then it would mean some of our assumptions were incorrect.
Bentley Pharmaceuticals, Inc. used pigs to perform the in vivo tests for
intranasal insulin delivery with CPE-215® formulations. The results showed that
right after the spray of certain intranasal insulin formulations into the pigs’ noses,
the body glucose level in the pigs dropped quickly, which indicated the insulin did
go through the nasal membranes with the help of CPE-215® and into the blood
system. CPE-215® is an effective membrane permeation enhancer for insulin.
Formulation lacking the enhancer showed no alterations in blood insulin level.
Since the animal test is not the object of this thesis and the test results are
proprietary of Bentley Pharmaceutical, we will not talk about it in detail here.
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CHAPTER 3
PROTEIN RELEASE FROM LIPOSOMES

In order to study the property and function of CPE-215® as a permeation
enhancer for natural membranes, we performed some insulin release
experiments with our liposome model under different conditions.
As described in the last chapter, liposomes are used to contain the
fluorescein-tagged insulin solutions, then different CPE-215® formulations are
added externally, and external insulin fluorescence is measured. Different
formulations provided insight on factors causing release.

3.1. General Procedure for One Release Experiment
First, about 0.1 g of lipid mixture (sometimes DPPC lipid only, sometimes
mixture of 4:1 (w/w) DPPC/cholesterol) was dissolved in 4 ml of chloroform to
assure a homogeneous mixture of lipids. Once the lipids were thoroughly mixed
in chloroform, the chloroform was removed by rotary evaporation yielding a thin
lipid film on the side of a 50-ml round bottom flask. The lipid film was thoroughly
dried to remove residual chloroform by placing the flask under vacuum overnight
at room temperature. Then 8 ml 0.2 mg/ml fluorescein-tagged insulin pH 7
phosphate buffer solution was added into the flask to hydrate the dry lipid film at
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50 °C, which allowed the lipid to hydrate in its fluid phase with adequate
agitation. A ten-second bath-type sonication was found to greatly reduce the
hydration time, making the sizing process easier and improving the homogeneity
of the size distribution. The product of hydration was a suspension of large,
multilamellar liposomes analogous in structure to an onion, with each lipid bilayer
separated by a water layer.89 Typically liposome suspensions were extruded five
times through a 400 nm pore size polycarbonate membrane filter at 50 °C
(Attempts to extrude below the Tc of lipids were unsuccessful as the membrane
has a tendency to foul with rigid membranes which cannot pass through the
pores).
After extrusion, centrifugal extraction was carried out to remove the
unencapsulated tagged insulin molecules. To make sure the liposomes were free
of external insulin, 6 ml of liposome suspension was centrifuged at 650 g for 30
minutes at 4 °C, then the supernatant was taken out and fresh 50 mM pH 7
phosphate buffer was added, and then the same procedure was repeated. Ten
cycles of centrifugal extraction were performed.
The process of liposome extrusion and centrifugal extraction can result in
some lipid loss. W e did one blank run (extrude liposome suspension without
insulin, after 10 cycles of centrifugal extraction, dry the remaining liposome
suspension to determine the dry lipid content) to determine how much lipid was
left after the process of liposome extrusion and centrifugal extraction, and found
that 70% of lipid content was left after the process.
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After the centrifugal extraction, the “cleaned” liposomes were evenly
distributed into six 15-ml plastic centrifuge tubes, which were used as the
containers for the release experiments. According to the requirement of the
experiment, buffer (most of the time, it was 50 mM pH 7 phosphate buffer) and
different excipients were added to the tubes. Usually one of the tubes was used
as blank release (no permeation excipient added). Finally each tube had 4 ml of
liposome suspension inside, and an aliquot sample was taken from each tube for
the release value at time=0. The centrifuge tubes were fit in the necks of the
three-neck jacketed flasks, which were on a shaker table and connected to the
temperature controlled water bath. The shaker table was set to 150 rpm
arbitrarily, and the influence of this shear parameter was not studied, though it
would be expected to have influence on the release results.
At various times, 400 pi of liposome sample was taken from each tube.
After 20 minutes’ centrifuging at 500 g at 4 °C, 200 pi supernatant of each 400 pi
sample was taken for the centrifugal filtration process at 500 g at 4 °C for another
30 minutes. A membrane filter with the nominal molecular weight limits (NMWL)
of 50 KDa was usually used to retain the liposomes and let insulin molecules go
through. 40 pi of the filtrate was diluted with the 50 mM pH 7 phosphate buffer to
400 pi for the final fluorescence measurement.
Finally, 100% release was achieved by sonicating the remaining
liposomes in the presence of Triton X-100 to break the lipid bilayers. Triton X-100
(Figure 24) is a strong water-soluble surfactant, which disrupts the bilayer
packing of liposomes and makes them leak.
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Figure 24 Chemical structure of Triton X-100.

The reproducibility of the release data has been improved over the course
of this study. Release data were estimated to have a reproducibility error of 10%
for Section 3.2 to 3.3. This error was reduced to 3-5% in Section 3.4 to 3.6. Only
a very limited data set was reproduced in Section 4.4.3 towards the end of this
study and the error was found to be less than 2%. The relative trend of the
release data (i.e. which sample had the faster/slower release rate) was
reproducible.
Point #0 for each sample was taken right after the emulsion/suspension
was added into the release tubes (before that, everything inside each tube was
identical), so theoretically their signals should be identical. However, practically
the liposomes release insulin even at low temperature. Only after centrifugal
filtration is complete, the outside insulin concentration is constant. The centrifugal
filtration process for each sample took about half an hour, from the time taking
the samples out to the end of the centrifugation. The signal difference of the
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Point #0 between the various formulations partially indicates the membrane
permeation enhancing effects of different formulations during the first 30 minutes.

3.2. Insulin Release from DPPC Liposomes at Different Temperatures
At first, we used only DPPC to prepare the liposomes. The transition
temperature of DPPC lipid bilayer is 42 °C. Below this temperature, the lipid is in
the rigid gel state; above it, the lipid is in the so called liquid crystalline state, with
freedom of motion in 2 dimensions without true melting. The liquid crystalline
state is the structural basis allowing mobility of membrane components within an
organized framework. The dynamic properties of membranes rely on the fluid
environment within the plane of the membrane, which means in the natural
membranes the overall transition temperature of the lipids is below 37 °C. In
order to make our liposome system more closely resemble the natural membrane
situation, higher release temperatures were used.

3.2.1. Insulin Release from DPPC Liposome at 47 °C At pH 7
An insulin release experiment of DPPC liposome at 47 °C was conducted,
which is 5 °C higher than the phase transition temperature of DPPC. Equal
amount and same concentration of DPPC liposomes in 50 mM pH 7 phosphate
buffer were put in three 15-ml plastic centrifuge tubes; pH 7 phosphate buffer,
cottonseed oil emulsion and CPE-215®/cottonseed oil emulsion were added into
three tubes respectively. The amount of CPE-215® is based on the molar ratio of
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CPE-215®: DPPC = 1:2, the weight ratio of CPE-215®: cottonseed oil = 3:1. The
tubes were placed into the 47 °C water bath on a shaker table at 150 rpm.
Figure 25 shows that the insulin release from DPPC liposome at 47 °C
was so fast that most of the insulin came out in 6 hours; and the temperature was
so high that there was almost no difference between the insulin release rates
among the three different tubes. At this temperature, the lipid bilayer was already
too permeable
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Figure 25 Insulin release from DPPC liposomes at 47 °C at pH 7. In the
“Blank” sample, there were only DPPC liposomes encapsulating insulin
solution. In “Cottonseed oil” sample, besides DPPC liposomes, there was
some cottonseed oil added. In “CPE&Cottonseed oil” sample, besides
DPPC liposomes, there was some mixture of 3:1 (w/w) CPE215®/Cottonseed oil added.
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This was the first insulin release experiment. Therefore, there were some
flaws in it. I did not expect the release rates to be that fast, and I did not take
samples in the first 6 hours and missed most of the information at the beginning.
In later release experiments, the sampling rate was increased at early times. In
Figure 25, although the trend of the data points was increasing with time, for one
sample (either “Blank”, or “Cottonseed oil”, or “CPE&Cottonseed oil”), some
release points at later time even had lower fluorescence signals than the earlier
ones. Theoretically, since those points were taken from the same release tube at
different times, the later sample points should not have lower fluorescence
signals than the earlier ones. That problem might be due to my sample handling
techniques, which needed to be improved. However, from this experiment, we
did know that 47 °C was too high for the DPPC liposome release experiments,
and we needed to use lower temperature for the future release experiments.

3.2.2. Insulin Release from DPPC Liposome at 42 °C at pH 7.4
Since we did not want to perform D P P C liposome release experiments at
temperature below the phase transition temperature of D P P C , and 47 °C was
proven to be too high, we decided to carry out the release experiment at the
phase transition of D P P C (42 °C ). This time we would like to see the individual
effect of cottonseed oil and C P E -2 15 ® on the insulin re le a se from D P P C

liposomes at pH 7.4.
DPPC liposomes were made with pH 7.4 tagged insulin phosphate buffer
solution. Three different release samples were made - one at pH 7.4 with CPE-
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215® suspension only, one at pH 7.4 with cottonseed oil suspension only, the last
one at pH 7.4 was the blank control. In each 15-ml plastic centrifuge tube, there
was 4 ml DPPC liposome buffer suspension with 0.0076 g DPPC inside; 1 g of
different emulsion/suspension was added later. CPE-215® was handled in a
warm water bath so that it was in the liquid state (mp 34 °C). This time the CPE215® amount was based on the molar ration of CPE-215®: DPPC = 125:1.
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Figure 26 Insulin release from DPPC liposome at 42 °C at pH 7.4. In the
“Blank" sample, there were only DPPC liposomes encapsulating insulin
solution. In “Cottonseed oil” sample, besides DPPC liposomes, there was
some cottonseed oil added. In “CPE-215” sample, besides DPPC
liposomes, there was some CPE-215® added. The amount of CPE-215®
added was based on the molar ratio of CPE-215®: DPPC = 125:1.
Cottonseed oil amount was based on CPE-215®: cottonseed oil (w/w) =
3:1.
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The release tubes were placed in a 42 °C water bath on a shaker table at
150 rpm. In the “CPE215” sample, most of the CPE-215® was on the top of the
solution; phase separation was due to its low solubility in water and its low
density. Oil-water phase separation happened in “Cottonseed oil” sample, too.
In Figure 26, those Point #0s are different, which partially indicates that
CPE-215® and cottonseed oil do have permeation enhancing effects on the
DPPC liposome release capacity. The sequence of initial fluorescence signals
from high to low is “Cottonseed oil”, “CPE215”and “Blank”.
Insulin release in “Cottonseed oil” was the fastest at the beginning, while
insulin release in “CPE215” was the slowest. But the release rate of “Cottonseed
oil” slowed down after it reached certain point, and finally was caught up by
“CPE215” and “Blank”. In this group, it seems that the sample releasing the
fastest (“Cottonseed oil”) at the beginning had the lowest data point in the end,
while the slowest one at the beginning (“CPE215”) had the highest data point. It
seems that cottonseed oil can help make a burst release at the beginning while
CPE-215® can keep the release from liposome at a higher rate. According to the
literature90, cottonseed oil is a mixture of triglycerides. 18-carbon fatty acids with
two unsaturated double bonds count for 53% of the total amount of fatty acids in
cottonseed oil. Cottonseed oil is a mixture of lipids, similar to DPPC. Therefore, it
can have good interactions with the lipids in the liposomes, which may account
for its membrane permeation enhancing effect.
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3.3. Insulin Release from DPPC Liposomes with Phase Transfer Agent
CPE-215® is a crystalline solid at room temperature, and cottonseed oil is
added to lower its melting point. The CPE-215®/cottonseed oil mixture is very
hydrophobic and not soluble in aqueous solutions. During the release
experiments, most of the CPE-215®/cottonseed oil mixture was phase-separated
from the aqueous buffer solution and floating on the top, which means most of
the CPE-215® added into the system did not have the chance to make contact
with liposomes, let alone help the release of insulin. In order for the permeation
excipient to take effect, how much and how fast CPE-215® can interact with the
liposomes and be incorporated in the lipid bilayer is more important than how
much CPE-215® emulsion is added to the system. Only the soluble portion of
CPE-215®, which is very limited, counts. This is the interpretation of why the
release enhancement effect of CPE-215® was so small in previous experiment.
Getting more CPE-215® into the lipid bilayer may be the key for faster
release rate. W e need a phase-transfer carrier to transport more CPE-215® from
the oil phase through the water phase to the liposome membrane to facilitate the
release of insulin out of the liposomes. Cyclodextrins are well-known for their
phase transport properties.
Structurally, Cyclodextrins consist of 6 , 7, or 8 (a, |3 and y respectively) Dglucopyranosyl units connected by alpha-(1,4) glycosidic linkages. Figure 27
shows the molecular structure of a-cyclodextrin. The most stable three
dimensional molecular configuration for these non-reducing cyclic
oligosaccharides takes the form of a toroid with the upper (larger) and lower
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(smaller) opening of the toroid presenting secondary and primary hydroxyl
groups, respectively, to the solvent environment. The interior of the toroid is
hydrophobic as a result of the electron rich environment provided in large part by
the glycosidic oxygen atoms, which can be used to carry or encapsulate small
water-insoluble molecules.

HOCH,

Figure 27 Molecular structure of a-cyclodextrin.

Table 1 Physical properties of various cyclodextrins91
Alpha
972
6
5
14.2
255-260
6

Molecular weight
Glucose monomers
Internal cavity diameter (angstroms)
Water solubility (g/100ml, at 25 °C)
Melting rang (°C)
Water molecules in cavity

Beta
1135
7
6
1.85
255-265
11

Gamma
1297
8
8
23.2
240-245
17

According to the information from Table 1, one more glucose unit in
cyclodextrin can result in huge cavity volume increase, it is surprising that the
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water solubility of p-cyclodextrin is only about 1/10 of that of a- or y-cyclodextrin.
y-Cyclodextrin has the largest internal cavity, but it is much more expensive than
the other two and not economical to use. p-Cyclodextrin is the cheapest among
the three and has a larger cavity than a-cyclodextrin, so P-cyclodextrin was used
as the promising phase transfer candidate.

V

N»

Figure 28 Molecular model of a-cyclodextrin (left) and CPE-215® (right) in
the same scale. Hydrogen atoms are white, carbon atoms are grey, and
oxygen atoms are red. a-Cyclodextrin is in a rod model, and CPE-215® is
in a stick-and-ball model.

Figure 2 8 show s the m olecular m odel of a-cyclodextrin and C P E -2 15 ® at

the same scale. It seems that the internal cavity of a-cyclodextrin is large enough
for a CPE-215® molecule.
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3.3.1. Insulin Release from DPPC Liposome at 42 °C with Cyclodextrins at
pH 7

We decided to add cyclodextrins to our release formulations to see if they
can work as phase transfer carriers as we expected. First we would like to know
if cyclodextrin can further enhance the permeation effect of CPE-215® and
cottonseed oil, then we would like to know if cyclodextrin itself has permeation
enhancing effect, and determine which cyclodextrin is better (alpha or beta).
We used a release tube with only DPPC liposomes inside as the blank
control; p-cyclodextrin buffer solution was added in one DPPC liposome
suspension as the “B-CD” sample to see the membrane permeation enhancing
effect of p-cyclodextrin itself; CPE-215®/Cottonseed oil mixture emulsion was
added to one DPPC liposome tube as the “CPE&CSO” sample to see the
membrane permeation enhancing effect of CPE-215®/Cottonseed oil mixture;
CPE-215®/Cottonseed oil mixture in p-cyclodextrin buffer solution was added into
one DPPC liposome tube as the “B-CD+CPE&CSO” sample to see if the
presence of P-cyclodextrin can further boost the effect of CPE-215®/Cottonseed
oil mixture; CPE-215®/Cottonseed oil mixture in a-cyclodextrin buffer solution
was added into one DPPC liposome tube as the “a-CD+CPE&CSO” sample to
see if a-cyclodextrin is better than p-cyclodextrin.
Phosphate buffer at pH 7 was used to make liposomes and prepare
different release samples. Five different 1 g emulsion/suspension formulations
were added to the identical liposome suspension in five release tubes, each with
4 ml DPPC liposome buffer suspension and 0.0063 g DPPC inside: one was the
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blank control buffer solution, one was the p-cyclodextrin buffer solution, one was
the p-cyclodextrin buffer solution with mixture of CPE-215® & cottonseed oil, one
was the simple mixture of CPE-215® & cottonseed oil, one was the a-cyclodextrin
buffer solution with mixture of CPE-215® & cottonseed oil.
The amount of CPE-215® added was based on a molar ratio of CPE-215®:
DPPC = 125:1. The amount of cyclodextrin was planned to be added according
to the weight ratio of CPE-215®: cyclodextrin = 2:1, but unfortunately, neither acyclodextrin nor p-cyclodextrin could be dissolved to that extent in the buffer
solution, so saturated cyclodextrin solutions were used (a-cyclodextrin is much
more water soluble than p-cyclodextrin).
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Figure 29 Insulin release from DPPC liposomes with cyclodextrins at 42
°C at pH 7. Sample tube with DPPC liposomes only was the “Blank”; Pcyclodextrin buffer solution was added in one DPPC liposome suspension
as the “B-CD” sample; CPE-215®/Cottonseed oil mixture emulsion was
added to one DPPC liposome tube as the “CPE&CSO” sample; CPE215®/Cottonseed oil mixture in P-cyclodextrin buffer solution was added
into one DPPC liposome tube as the “B-CD+CPE&CSO” sample; CPE21 5®/Cottonseed oil mixture in a-cyclodextrin buffer solution was added
into one DPPC liposome tube as the “a-CD+CPE&CSO” sample.

The release tubes were placed in a 42 °C water bath on a shaker table at
150 rpm. Figure 29 shows the result of this insulin release experiment with
cyclodextrins at pH 7.
All samples showed similar release pattern: insulin release rates were
very fast at the very beginning (ideal for intranasal drug delivery), followed by
slower rate after 10 hours, but different samples showed different starting points.
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The experimental data showed that the sample with a-cyclodextrin buffer
solution and mixture of CPE-215® & cottonseed oil had the highest starting point
and the fastest release rate at the beginning; the next one was the one with (3cyclodextrin and mixture of CPE-215® & cottonseed oil. The blank control one
had the lowest starting point and the slowest release rate, as expected. For the
ones with only P-cyclodextrin or mixture of CPE-215® & cottonseed oil, it is hard
to tell which one is faster; they have almost the same effects on the release of
insulin.
All the samples with cyclodextrin show obvious permeation enhancement
effects, and saturated a-cyclodextrin solution has better effect than saturated pcyclodextrin solution due to the big difference in water solubility. Cyclodextrin
itself has just a small permeation enhancing effect; it mainly acts as a phase
transfer carrier.
Finally, CPE-215® is an effective permeation enhancer, but needs a phase
transition carrier like cyclodextrin; otherwise it can reach the membrane only with
great difficulty due to its limited water solubility.

3.3.2. Insulin Release from DPPC Liposome at 42 °C with Different Amount
of Cyclodextrins at pH 7
W e h ave known that cyclodextrin can further e n h a n c e th e m em brane

permeation effect caused by CPE-215® and cottonseed oil, now we would like to
know how much cyclodextrin is needed and what the proper ratio of CPE-215® to
cyclodextrin is.
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This time, we added the same amount of CPE-215®/Cottonseed oil
mixture with different amount of a-cyclodextrin into each liposome suspension to
determine the best ratio of cyclodextrin to CPE-215®. In the previous experiment,
saturated a-cyclodextrin showed better permeation enhancing effect with CPE215® than saturated P-cyclodextrin, but in that case, much more a-cyclodextrin
was added than P-cyclodextrin due to higher solubility of a-cyclodextrin, so it is
difficult to determine which one is better. This time we compared a-cyclodextrin
with p-cyclodextrin at the same molar ratio of CPE-215®.
Similar amount of 3:1 (w/w) CPE-215®/Cottonseed oil mixture were added
to every release tube. The amount of CPE-215® added was based on the molar
ratio of CPE-215®: DPPC = 20:1. A 50 mM pH 7 phosphate buffer was used to
make liposomes and prepare different release samples. Three liposome samples
were used to see the effect of different amount of a-cyclodextrin on the insulin
release rate. In “C&C+1x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215®
= 1:100; in “C&C+5x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215® =
1:20; in “C&C+20x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215® = 1:5.
In “C&C+20x B-CD” sample, molar ratio of P-cyclodextrin: CPE-215® = 1:5.

79

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

80 n

60

c
3

V)
c

C&C+20X B-CD
C&C+1xa-CD
C&C+5x a-CD
C&C+20X a-CD

0

H-----------------1-----------------i-----------------1-----------------i-----------------i---------------- 1-----------------i

0

4

8

12

16

20

24

28

!

i

i

i

32

36

40

44

>

48

Time (hour)

Figure 30 Insulin release from DPPC liposomes at 42 °C at pH 7 with
different ratio of cyclodextrin over CPE-215®. Same amount of 3:1 (w/w)
CPE-215®/Cottonseed oil mixture was added to every release tube. The
amount of CPE-215® added was based on the molar ratio of CPE-215®:
DPPC = 20:1. In “C&C+1x a-CD” sample, molar ratio of a-cyclodextrin:
CPE-215® = 1:100; in “C&C+5x a-CD” sample, molar ratio of acyclodextrin: CPE-215® = 1:20; in “C&C+20x a-CD” sample, molar ratio of
a-cyclodextrin: CPE-215® = 1:5. In “C&C+20x B-CD” sample, molar ratio
of (3-cyclodextrin: CPE-215® = 1:5.

The release tubes were placed in a 42 °C water bath on a shaker table at
150 rpm. Figure 30 showed the results of this insulin release experiment with
different amounts of cyclodextrin at 42 °C at pH 7. The shapes of the four insulin
release curves were similar: the release rate was very fast at the very beginning,
then the insulin release rate slowed down and after 6 hours reached a gentle
slope. The starting points for each release curve were not the same. We could
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almost predict which sample would have the maximum final insulin release by
looking at the insulin fluorescence signals at Time Zero - the higher the
fluorescence signal at Time Zero, the more final released insulin for that sample.
By comparing the release curves, we can see that the more cyclodextrin,
the more insulin released from DPPC liposomes; at the same molar ratio to CPE215®, P-cyclodextrin is better than a-cyclodextrin, which makes sense because Pcyclodextrin has a bigger hydrophobic cavity than a-cyclodextrin.

3.3.3. Insulin Release from DPPC Liposome at 42 °C with Beta-Cyclodextrin
at pH 7
In order to know the effect of p-cyclodextrin on different components of the
intranasal formulation, such as CPE-215®, cottonseed oil and mixture of CPE215® and cottonseed oil, we carried out another insulin release experiment.
“Cleaned” DPPC liposomes encapsulating insulin pH 7 phosphate buffer
solution were evenly divided into four plastic centrifuge tubes. As usual we used
one tube of DPPC liposomes as the “Blank” sample. In “CSO+B-CD” sample,
cottonseed oil in pH 7 p-cyclodextrin buffer solution was added; in “CPE+B-CD”
sample, CPE-215® in pH 7 P-cyclodextrin buffer solution was added; in
“CPE+CSO+B-CD” sample, CPE-215®/Cottonseed oil mixture in P-cyclodextrin
buffer solution was added. We used 2% p-cyclodextrin buffer solution, which is
almost its saturation concentration. The amount of CPE-215® added was based
on the molar ratio of CPE-215®: P-cyclodextrin =1:1, molar ratio of DPPC: CPE-
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215® = 1:5. The 50 mM pH 7 phosphate buffer was used to prepare liposomes
for these different release samples.
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Figure 31 Insulin release from DPPC liposomes at 42 °C with (3cyclodextrin at pH 7. In “Blank” sample, there was only DPPC liposomes,
as the blank control for insulin release. In “CSO+B-CD” sample,
cottonseed oil in pH 7 P-cyclodextrin buffer solution was added into
liposomes: in “CPE+B-CD” sample, CPE-215® in pH 7 P-cyclodextrin
buffer solution was added into liposomes; in “CPE+CSO+B-CD” sample,
CPE-215®/Cottonseed oil mixture in p-cyclodextrin buffer solution was
added into liposomes. The amount of CPE-215® added was based on the
molar ratio of CPE-215®: P-cyclodextrin =1:1, molar ratio of DPPC: CPE215® = 1:5.

The release tubes were placed in a 42 °C water bath on a shaker table at
150 rpm. Figure 31 showed the insulin DPPC liposome release result of pcyclodextrin with different formulation components. There was also a very fast
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release rate at the very beginning, then the rate slowed down and reached a
plateau. The insulin released from liposomes in “Blank” sample was the smallest,
as expected. Although the “Blank” here was different from the “Blank” in Figure
26 , which meant we had some reproducibility issue, the relative trends of them
were similar. The amounts of insulin released in “CPE+B-CD” and
“CPE+CSO+B-CD” samples were average; the “CSO+B-CD” sample had the
maximum insulin release. It is interesting to see that cottonseed oil showed better
membrane permeation enhancing effect than CPE-215® in this experiment. In
comparison with previous results of insulin release experiments, we can say (3cyclodextrin can further enhance the insulin release from DPPC liposomes.
Based on the structure of cyclodextrins and the results of the insulin
release experiments, we confirmed that cyclodextrins increased the availability of
CPE-215® and cottonseed oil to the liposomes. Cyclodextrins and the
hydrophobic CPE-215®/ cottonseed oil formed inclusion complexes by
hydrophobic interaction and when the cyclodextrins collided with the liposomes,
CPE-215® and cottonseed oil could be released into the hydrophobic lipid
bilayers of liposomes. The direct conclusion out of this hypothesis is that
cyclodextrin could greatly increase the apparent solubility of CPE-215® in water.
However, in a simple solubility test of CPE-215® in (3-cyclodextrin solution, even
when the molar ratio of (3-cyclodextrin: CPE-215® reached to 10:1, we could still
see some CPE-215® floating on the aqueous surface. Probably (3-cyclodextrin did
increase the solubility of CPE-215® in water, maybe by 10 or 100 fold, but not as
much as we thought (we thought by forming an inclusion complex with CPE-
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215®, one p-cyclodextrin could take one CPE-215® into the aqueous phase). I did
a literature search on cyclodextrins, and found that cyclodextrins were widely
used to increase the water solubility of hydrophobic molecules by forming a 1:1
inclusion complex; but not every cyclodextrin molecule could form a complex with
those hydrophobic molecules, there were different formation constants for
different molecules. In one recent paper on the use of P-cyclodextrin to increase
the solubility of a highly hydrophobic drug, furosemide, the drug solubility was
increased by 11 fold with the help of cyclodextrin.92

3.4. Incorporating Cholesterol into DPPC Liposome
Cholesterol is a membrane constituent widely found in animal systems
which serves a unique purpose of modulating membrane fluidity, elasticity, and
permeability. In order to make our liposome model more similar to natural
membrane, cholesterol was incorporated with DPPC to prepare the liposomes.
The fluid-phase behavior of binary mixtures of cholesterol with
phosphatidylcholines was well studied.93,94 When cholesterol content is higher
than 30 mol%, there is only one phase in DPPC and cholesterol mixture from 20
°C to 55 °C. In order to make cholesterol evenly distributed in the lipid bilayer, the
weight ratio of DPPC to cholesterol in our new membrane model was 4:1, in
which cholesterol counts for 32 mol% of total lipid. With this adjustment to the
liposome model, the insulin release temperature was adjusted to the human body
temperature of 37 °C.
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3.4.1. Insulin Release at 37 °C from DPPC/Cholesterol Liposomes with
Different Formulation Components and Simple Combinations
After we decided to incorporate cholesterol into DPPC liposomes, we
wanted to see if the change in the liposome model and temperature could result
in a change of the insulin release profile. W e wanted to see the effect of CPE215® only, cottonseed oil only and with (3-cyclodextrin combination on this
improved membrane model. Therefore, we did a similar insulin release
experiment for this DPPC/Cholesterol liposome at 37 °C.
W e used a high molar ratio of P-cyclodextrin: CPE-215®, which was 1:1.
Due to the solubility limitation of P-cyclodextrin, the molar ratio of CPE-215®:
DPPC turned out to be 4:1. Cottonseed oil is a mixture of triglycerides with the
average molecular weight of 275. In this experiment, the molar ratio of (3cyclodextrin: cottonseed oil was also 1:1. A 50 mM pH 7 phosphate buffer was
used to prepare these liposomes.
“Cleaned” DPPC/Cholesterol liposomes encapsulating insulin phosphate
buffer solutions were evenly divided into six plastic centrifuge tubes, with 2 ml of
DPPC/Cholesterol liposomes in each tube. We added 2 ml of pH 7 buffer into
one tube of liposomes and used it as the “Blank” control sample. In the “CPE-215
only” sample, CPE-215® and 2 ml of pH 7 phosphate buffer were added to the 2
ml liposomes; in the “Cottonseed oil only” sample, cottonseed oil and 2 ml of pH
7 phosphate buffer were added to the liposomes; in the “ 1:1 B-cyclodextrin: CPE215” sample, CPE-215® and 2 ml of 2% (3-cyclodextrin pH 7 phosphate buffer
solution were added to the 2 ml liposomes; in the “ 1:1 B-cyclodextrin: CSO”
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sample, cottonseed oil and 2 ml of 2% p-cyclodextrin pH 7 phosphate buffer
solution were added to the 2 ml liposomes.
In this experiment, we also wanted to see the effect of different oil droplet
size of cottonseed oil on the insulin release profile. In “Cottonseed oil only” and
“1:1 B-cyclodextrin: CSO” samples, cottonseed oil was added as droplets.
However, in the “CSO emulsion” sample, cottonseed oil was added to the
liposomes in the form of emulsion made with a high shear mixter (Ultra Turrex®).

Table 2 Samp e information in Section 3.4.1
Sample
Content
Blank
2 ml liposome +2 ml phosphate
buffer
CPE-215 only
2 ml liposome +2 ml phosphate
buffer+CPE-215®
Cottonseed oil only 2 ml liposome +2 ml phosphate
buffer+ cottonseed oil drop
CSO emulsion
2 ml liposome +2 ml cottonseed oil
emulsion
1:1 B-cyclodextrin:
2 ml liposome +2ml 2% P-CD buffer
CPE-215
solution + CPE-215®
1:1 B-cyclodextrin:
2 ml liposome +2ml 2% P-CD buffer
CSO
solution + cottonseed oil drop

Note
The amount of
CPE-215® used in
different samples
was the same, so
was cottonseed oil.
The amount of
CPE-215® and
cottonseed oil used
was based on 1:1
molar ratio to P-CD.

Before the experiment, we thought since CPE-215® crystal started to melt
at 34 °C, it would be in liquid state at 37 °C. But during the release experiment at
37 °C, in the samples containing CPE-215®, we could see some solid CPE-215®
floating on the aqueous surface, which further decreased the availability of CPE215® to the liposomes. Consequently, in all the further release experiments at 37
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°C, CPE-215® was added in company of cottonseed oil, in order to eliminate solid
CPE-215® phase.
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Figure 32 Insulin release from DPPC/Cholesterol liposomes at 37 °C at
pH 7. In the “Blank” sample, there was only DPPC/Cholesterol liposomes,
as the blank control for insulin release. Molar ratio of (3-cyclodextrin: CPE215®: cottonseed oil = 1:1:1.

Figure 32 showed the result of insulin release from DPPC/Cholesterol
liposomes at 37 °C at pH 7. The release data were good and as expected—the
data curve of the “Blank” sample was the lowest among all the sample release
curves, and the released insulin signals increased with time in all the samples. All
the insulin release data points are independent, which means that there is no
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guarantee for fluorescence signal of the next point to be higher than the one
before, although it should be— any mistakes can result in unreasonable curves.
Therefore, a reasonable curve (the fluorescence signals increase with time and
the “Blank” curve shows the slowest release) not only shows the insulin release
information, but also shows that the experimental procedures (sample handling,
liposome separation and fluorescence signal measurement, etc.) were done
properly. The reproducibility of our data was also good.
From Figure 32, we can establish a list of samples from the minimum
amount of released insulin from DPPC/Cholesterol liposomes to the maximum
amount of released insulin, and comes in order “Blank”, “CPE-215 only",
“Cottonseed oil only”, “CSO emulsion”, “1:1 B-cyclodextrin: CPE-215” and “1:1 Bcyclodextrin :CSO”. The difference between “Cottonseed oil only” and “CSO
emulsion” samples was really small, which shows that the difference in the oil
droplet size of cottonseed oil did not make a difference in the insulin release
profile. Since adding oil droplets is much easier than making oil emulsions, in the
following experiments, cottonseed oil and mixture of CPE-215®/Cottonseed oil
were added into DPPC/Cholesterol liposomes as large oil droplets.
This experiment showed again that adding (3-cyclodextrin could further
enhance the insulin release from liposomes and cottonseed oil had better
membrane permeation enhancing effect than CPE-215®. CPE-215® is a good
permeation enhancer, but needs a phase transfer carrier to increase its
availability to the liposomes.
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3.4.2. Insulin Release at 37 °C from DPPC/Cholesterol Liposomes with
Different amount of CPE-215®
From the results of previous insulin release experiments with
cyclodextrins, it seemed that the insulin release was controlled by the availability
of CPE-215® to the liposomes, not by the amount of CPE-215® added into the
release tube. If that conclusion is true, then under the same conditions, adding
more CPE-215® into the release tube will not make the insulin release rate from
liposomes faster, since the water is already saturated with CPE-215®. In order to
test this theory, we designed a new release experiment.
This time, we used six release tubes. One was still used as blank control;
one was used to see the permeation enhancing effect of (3-cyclodextrin only,
without CPE-215®; two were used to compare the insulin release rate with
different amount of CPE-215®/Cottonseed oil mixture; the last two were used to
compare the insulin release rate with different amount of CPE-215®/Cottonseed
oil mixture with the same amount of (B-cyclodextrin present.
In DPPC/Cholesterol liposome, weight ration of DPPC: cholesterol was
still 4:1. The weight ratio of CPE-215®: cottonseed oil was still 3:1. In the “ 1X
CPE&CSO” sample, molar ratio of CPE-215®: DPPC was 4:1; in the “3X
CPE&CSO” sample, molar ratio of CPE-215®: DPPC was 12:1. In the
“1XCPE&CSO+B-CD”, molar ratio of (3-cyclodextrin: CPE-215®: DPPC was 4:
4:1; in the “3XCPE&CSO+B-CD” sample, molar ratio of (3-cyclodextrin: CPE215®: DPPC was 4:12:1. In the “B-CD only” sample, molar ratio of (3-cyclodextrin:
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DPPC was 4:1. A 50 mM pH 7 phosphate buffer was used to prepare these
liposomes.

Table 3 Sample information in Section 3.4.2
^ I 11 O H
Sample
CPE-215®:Cottonseed
oili
(weight)
Blank
N/A
B-CD only
N/A
1X CPE&CSO
3:1
3X CPE&CSO
3:1
1XCPE&CSO+B-CD
3:1
3XCPE&CSO+B-CD
3:1

CPE-215 :DPPC:p-CD
(molar)
N/A
0:1:4
4:1:0
12:1:0
4:1:4
12:1:4
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Figure 33 Insulin release at 37 °C from DPPC/Cholesterol liposomes with
different amount of CPE-215®/Cottonseed oil at pH 7. The weight ratio of
CPE-215®: cottonseed oil was still 3:1. In the “1X CPE&CSO” sample,
molar ratio of CPE-215®: DPPC was 4:1; in the “3X CPE&CSO” sample,
molar ratio of CPE-215®: DPPC was 12:1. In the “1XCPE&CSO+B-CD”,
molar ratio of (3-cyclodextrin: CPE-215®: DPPC was 4: 4:1; in the
“3XCPE&CSO+E3-CD” sample, molar ratio of (3-cyclodextrin: CPE-215®:
DPPC was 4:12:1. In the “B-CD only” sample, molar ratio of (3cyclodextrin: DPPC was 4:1.

Figure 33 showed the result of insulin release from DPPC/Cholesterol
liposomes with different amount of CPE-215®/Cottonseed oil mixture at pH 7.
The “Blank" sample showed a steady intrinsic insulin leakage rate from
DPPC/Cholesterol liposomes. The other samples all showed a much higher
insulin release rate than the “Blank” sample at the beginning, then the release
rates decreased and finally the insulin release rates were similar to the blank
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control. The “B-CD only” sample showed that p-cyclodextrin itself also had
membrane permeation enhancing effect, but the faster release rate only lasted
for about an hour, then went back down to the blank control rate. The
“ 1XCPE&CSO” sample had almost the same starting release rate as the “B-CD
only” sample, but lasted for a longer time, about 3 hours, then the rate went back
down to the blank control rate. The “3XCPE&CSO” sample had a little bit faster
stating release rate than the “1XCPE&CSO” sample, but not much. The
“1XCPE&CSO+B-CD” sample and the “3XCPE&CSO+B-CD” sample had almost
the same release profiles, though the amount of CPE-215®/Cottonseed oil in
these two samples was different; their insulin release rate was much faster than
the other samples. Obviously the fast insulin release rate was not due to the
simple effects of (3-cyclodextrin and CPE-215®/Cottonseed oil, but showed the
synergy between p-cyclodextrin and CPE-215®/Cottonseed oil on the membrane
permeation effect.
This experiment successfully supported the assumption that the insulin
release was controlled by the availability of CPE-215® to the liposomes, not by
the amount of CPE-215® added into the release tube. P-Cyclodextrin could
increase the availability of hydrophobic CPE-215® to the aqueous phase, which
resulted in great insulin release rate increases from “ 1XCPE&CSO” to
“1XCPE&CSO+B-CD”, and from “3XCPE&CSO” to “3XCPE&CSO+B-CD”. With
the same amount of P-cyclodextrin in the solution, which meant with the same
amount of “transporters” available, different amount of CPE-215® results in the
same insulin release rate.
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3.5. Insulin Release from DPPC/Cholesterol Liposomes at Different pH
Twenty different amino acids are the elementary constituents of all natural
proteins. Those amino acids can be grouped according to the characteristics of
the side chains, such as acidic, basic, polar, and non-polar. Changing pH
changes the charges on the acidic and basic amino acid side chains, and results
in changes in the total charge of the protein: the higher the pH value, the more
negative charge on the protein. For human insulin, the isoelectric point is aroud
pH 5.3.95 W e wished to see the effect of pH on the insulin release rate from
DPPC/Cholesterol liposomes. The change of pH could also affect the charge on
the lipids and the liposome structure, but the charge on DPPC does not change
in the pH range from 4 to pH 10.

3.5.1. Insulin Release from DPPC/Cholesterol Liposome at 37 °C with Small
pH Gradient
W e wanted to see what the insulin release profile would be when there is
a pH gradient across the membrane (the insulin solution inside of liposomes at
different pH value from the outside buffer solution). In this experiment, we tested
three gradients (inside to outside of liposome): pH 7 to pH 5.7, pH 7 to pH 7, pH
7 to pH 8.2. There were two samples for each gradient: one as the blank release
control, the other was added CPE-215®/cottonseed oil mixture and (3-
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cyclodextrin. However, the result was not what we expected. Finally we realized
that it is hard to keep a pH gradient across the lipid bilayer.
When we prepared the 4:1 (w/w) DPPC/Cholesterol liposomes, 50 mM pH
7 phosphate buffer was used, so that the insulin solution inside of liposome was
pH 7. When we did the centrifugal extractions at 4 °C, 50 mM pH 7 phosphate
buffer was also used. Then 3 ml of concentrated liposomes were evenly
distributed into six 15-ml plastic centrifuge tubes. In “pH 5.7 Blank” , 3.5 ml of pH
5 phosphate solution was added to 0.5 ml of pH 7 liposomes, the final pH turned
out to be 5.7. In “pH 7 Blank”, 3.5 ml of pH 7 phosphate buffer was added to 0.5
ml of pH 7 liposomes. In “pH 8.2 Blank”, 3.5 ml of pH 9 phosphate solution was
added to 0.5 ml of pH 7 liposomes, the final pH turned out to be 8.2. In “pH 5.7
C&C+B-CD”, 3.5 ml of 2% (3-cyclodextrin pH 5 phosphate solution and mixture of
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes. In “pH 7
C&C+B-CD”, 3.5 ml of 2% p-cyclodextrin pH 7 phosphate solution and mixture of
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes. In “pH 8.2
C&C+B-CD”, 3.5 ml of 2% p-cyclodextrin pH 9 phosphate solution and mixture of
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes.
The weight ratio of CPE-215®: cottonseed oil was still 3:1. The molar ratio
of CPE-215®: P-cyclodextrin: DPPC was 4:4:1.
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Figure 34 Insulin release at 37 °C from DPPC/Cholesterol liposomes at
different pH gradients, inside pH is 7. The 100% insulin release point was
0.0045 mg/ml. W e tested three gradients (inside to outside of liposome):
pH 7 to pH 5.7, pH 7 to pH 7, pH 7 to pH 8.2. There were two samples for
each gradient, one for the blank release control, the other was added
CPE-215®/cottonseed oil mixture and P-cyclodextrin. The weight ratio of
CPE-215®: cottonseed oil was still 3:1. The molar ratio of CPE-215®: Pcyclodextrin: DPPC was 4:4:1.

Figure 34 showed the result of insulin release from DPPC/Cholesterol
liposomes at different pH gradients. To our surprise, it seemed that the pH
gradients had no effect on the insulin release rate from liposomes: no matter at
what pH gradient, all the blank control samples seemed to have the same insulin
release rate, and all the samples with CPE-215®/Cottonseed oil and Pcyclodextrin had the same insulin release rate, too. The samples with CPE215®/Cottonseed oil and P-cyclodextrin showed much faster insulin release rates
at the beginning, similar to the previous release experiments at pH 7.
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In Figure 34, instead of showing the percent of total insulin release in the
Y-axis as before, insulin concentration was used as the Y-axis. The 100% insulin
release point corresponded to the insulin concentration of 0.0045 mg/ml.
After some literature search on the membrane permeability to protons, I
found that lipid bilayers are remarkably permeable to protons.96 It is clear that
proton permeability is at least 106 greater than for the other simple ions, and this
is true for biomembranes as well as for model membranes.97 Therefore, in our
experiment, due to the great permeability of protons through membrane, there
might not be a pH gradient between the inside and outside of liposomes, though
we tried to establish one; the release results are likely to have shown the insulin
release rates at pH around 6 , 7 and 8 , without pH gradients.

3.5.2. Insulin Release from DPPC/Cholesterol Liposome at 37 °C at pH 10
In order to find out how pH affects insulin release, we performed the
insulin release from 4:1 (w/w) DPPC/Cholesterol liposomes at pH 10. At pH 10,
insulin has a negative overall charge of about -5.
We did the liposome extrusion and the centrifugal extraction both at pH
10, so that we were certain there was no pH gradient from the inside to the
outside of the liposome. The liposomes were evenly distributed into three 15-ml
plastic centrifuge tubes. O n e tube w as used as blank release control, one

received a CPE-215®/Cottonseed oil mixture, the other one received a CPE215®/Cottonseed oil mixture and (3-cyclodextrin. The weight ratio of CPE-215®:
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cottonseed oil was still 3:1. The molar ratio of CPE-215®: p-cyclodextrin: DPPC
was 4:4:1.
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Figure 35 Insulin release at 37 °C from DPPC/Cholesterol liposome at pH
10. The 100% insulin release point was 0.003 mg/ml. The weight ratio of
CPE-215®: cottonseed oil was still 3:1. The molar ratio of CPE-215®: Pcyclodextrin: DPPC was 4:4:1.

Figure 35 showed the result of insulin release from DPPC/Cholesterol
liposomes at pH 10. Insulin concentration was used as the Y-axis. The 100%
insulin release point corresponded to the insulin concentration of 0.003 mg/ml.
Insulin release at pH 10 showed a similar trend: CPE-215®/Cottonseed oil
mixture could make more insulin come out of liposomes; adding P-cyclodextrin
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could further enhance the permeation effect of CPE-215®. However, compared
with the release data at pH 7 (Figure 33), insulin release at pH 10 seems more
difficult: slower release rate with low insulin blank release rate.

3.5.3. Insulin Release from DPPC/Cholesterol Liposome at 37 °C at pH 4
We also performed the insulin release from 4:1 (w/w) DPPC/Cholesterol
liposomes at pH 4. At pH 10, insulin has a positive overall charge, about +3.
We carried out the liposome extrusion and the centrifugal extraction at pH
4, so that we were certain that there was no pH gradient. The liposomes were
evenly distributed into three 15-ml plastic centrifuge tubes. One tube was used
as blank release control; “C&C” received a CPE-215®/Cottonseed oil mixture;
“C&C+B-CD” received a CPE-215®/Cottonseed oil mixture and P-cyclodextrin.
The weight ratio of CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE215®: p-cyclodextrin: DPPC was 4:4:1.
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Figure 36 Insulin release at 37 °C from DPPC/Cholesterol liposome at pH
4. The 100% insulin release point was 0.003 mg/ml. The weight ratio of
CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: pcyclodextrin: DPPC was 4:4:1.

Figure 36 showed the result of insulin release from DPPC/Cholesterol
liposomes at pH 4. Insulin concentration was used as the Y-axis. The 100%
insulin release point corresponded to the insulin concentration of 0.003 mg/ml.
Insulin release curve of “C&C” was only a little higher than the release curve of
“Blank”, but “C&C+B-CD” still showed much faster insulin release from
liposomes. Comparing the release data at pH 4 (Figure 36) and pH 7 (Figure 33),
we can see it is much harder for insulin to permeate through lipid bilayers at pH 4
than at pH 7, even with the help of CPE-215®/cottonseed oil and P-cyclodextrin.
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3.6. BSA Release at 37 °C from DPPC/Cholesterol Liposomes at pH 7
Previously we used insulin molecules, which were tagged with
fluorescence probes, to do the release experiments from liposomes with CPE215®, and found that liposomes are a good membrane model and CPE-215® is a
good membrane permeation enhancer. To see if CPE-215® is protein kind and
size specific, we used a larger protein instead of insulin (MW 6 KDa) to do
another release experiment. Bovine serum albumin (BSA, MW 66 KDa) was
selected to be the other model protein. In order to improve the detection
sensitivity, again we used the fluorescence labeling process to attach a
fluorescence probe to BSA.
We performed both the liposome extrusion and the centrifugal extraction
at pH 7. The 4:1 (w/w) DPPC/Cholesterol liposomes were evenly distributed into
three 15-ml plastic centrifuge tubes. One tube was used as the blank release
control; in the “CPE” sample, CPE-215® solid was added; in the “CPE&CSO”
sample, CPE-215®/Cottonseed oil mixture was added. The weight ratio of CPE215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: DPPC was 4:1.
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Figure 37 BSA release at 37 °C from DPPC/Cholesterol liposomes at pH
7. The 100% BSA release point was 0.007 mg/ml. The weight ratio of
CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: DPPC
was 4:1. In the “CPE” sample, CPE-215® solid was added; in the
“CPE&CSO” sample, CPE-215®/Cottonseed oil mixture was added.

Figure 37 showed the result of BSA release at 37 °C from
DPPC/Cholesterol liposomes at pH 7. BSA concentration was used as the Yaxis. The 100% BSA release point was 0.007 mg/ml. The BSA release data
showed that CPE-215® can also enhance the release of big proteins, for example
66 KDa BSA, through lipid bilayers. CPE-215®/Cottonseed oil mixture gave better
result than CPE-215® alone, maybe because at 37 °C, most of CPE-215® is still a
solid, making it less available to the liposomes than CPE-215®/Cottonseed oil
mixture. The BSA release rate with CPE-215®/Cottonseed oil was slow at the
beginning when compared with the insulin release data, which might be due to
the larger size of BSA.
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CHAPTER 4
RELEASE MECHANISM STUDY

The experiments of insulin release from liposomes have proved that CPE215® is an effective membrane permeation enhancer. The next step is to
investigate the mechanism behind the fact that CPE-215® facilitates the insulin
transport through lipid bilayers. Studies focusing on the properties of our system
were carried out, such as the insulin solution properties (self-diffusion and self
association states of insulin), the interaction between insulin and liposome and
the interaction between CPE-215® and liposomes. Based on these studies and
the experimental data, a hypothesis was proposed and the result of a special
testing experiment proved the validity of the hypothesis for the protein release
profile from liposomes.

4.1. Insulin Solution Properties

4.1.1. Insulin Diffusion Coefficient Measurement by NMR
N u c lea r M ag n etic R eso n an ce (N M R ) is a com m on non-destructive

technique, which is widely used to obtain information on functional group analysis
(chemical shifts), bonding connectivity and orientation (J coupling), through
space connectivity (Overhauser effect), molecular conformations, DNA, peptide
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and enzyme sequence and structure, etc. It can also be used to determine the
self-diffusion coefficient by the spin-echo technique with pulsed field gradient.98,99
Molecules in liquid or solution states move. This translational motion is, in
contrast to rotational motion, known as Brownian molecular motion and is often
simply called diffusion or self-diffusion. It depends on a lot of physical parameters
such as size and shape of the molecule, temperature and viscosity. Assuming a
globular or spherical shape for the molecule, the diffusion coefficient, D, is
described by the Stokes-Einstein equation

n

kT

6^

where

k

.

is the Boltzman constant,

1411
T

the temperature,

q

the viscosity of the liquid

and rsthe hydrodynamic radius of the molecule.
Pulsed field gradient NMR spectroscopy can be used to measure the
translational diffusion coefficient of molecules and is sometimes referred to as qspace imaging. Through the use of a gradient, molecules can be spatially
labeled, i.e. marked depending on their spatial position in the sample tube. If they
move after this encoding during the following diffusion time A, their new position
can be decoded by a second gradient. The measured signal is the integral over
the whole sample volume and the NMR signal intensity is attenuated depending
on the diffusion time A and the gradient parameters (g,

6).

This intensity change

is described by
r _

j

1 ~ 1o

„ - D r 2g 2s 2 ( A - s / Z )

[4.2]

e
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where

I

is the observed intensity,

lo

the reference intensity (unattenuated signal

intensity), D the diffusion coefficient, yth e gyromagnetic ratio of the observed
nucleus,

g

the gradient strength,

6

the length of the gradient, and A the diffusion

time. If bipolar gradients are used for dephasing and rephasing, a correction for
the time

t

between those bipolar gradients has to be applied:

T
IT = I0
'e - D y 2g 2S 2 ( A - S / Z - T / 2 )

[4.3]

Briefly, a spin echo pulse sequence is used in combination with a pair of
gradients on both sides of the 180° pulse. The echo amplitude decay was
measured and the value of the self-diffusion coefficient was determined from that
signal.
Usually in NMR experiments, the higher the concentration, the better the
signal/noise. We used low pH to dissolve more insulin in the NMR tube:
deuterated hydrochloride acid was used to adjust D2O to pH 3, which was near
the pH value of the intranasal insulin formulations of Bentley Pharmaceuticals,
and then insulin was dissolved to reach 2 mg/ml solution.

104

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

iili

it ii

Hi

i

FI

(■2*1

2
3-

4-

5
6
7-

8

• I
9

1---- '------

’-- 1----'
8

r

---7

1---- 1
----■----’---- 1----!---- 1---- 1----

6

1---- !----,_L"---- '---- '---- r----’--- 1

5

4

3

r

'---- 1---- ---------T

r

T

’----1

2

F2 ( p p « )

Figure 38 Insulin diffusion coefficient measurement by pulsed field
gradient NMR at pH 3 at 37 °C. The X-axis shows the chemical shifts of
TH NMR spectrum; the Y-axis shows the diffusion coefficient, the unit is
10‘10 m2/s, i.e. 10’6 cm2/s.

Figure 38 shows the insulin diffusion coefficient measured by pulsed field
gradient NMR at pH 3 at 37 °C. It is a 2D NMR spectrum: the X-axis shows the
1H NMR spectrum, the value in the Y-axis corresponds to the diffusion coefficient
of the molecule for that specific proton. This 2D NMR spectrum shows the
diffusion coefficients of different protons in the solution; therefore, even if there
are different molecules in the solution, as long as the chemical shifts can be
identified individually, the diffusion coefficients of different molecules can be
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obtained from the 2D DOSY NMR spectrum at the same time. In Figure 38, most
protons have the diffusion coefficient of 1.4 x 10' 10 m2/s, the other proton with a
chemical shift at 4.7 ppm has a much faster and broader diffusion coefficient.
Based on its chemical shift position and diffusion coefficient, the peak at 4.7 ppm
should be due to the proton of water molecules. Insulin consists of 51 amino
acids and should have a 1H NMR spectrum with numerous peaks. Therefore, the
remaining peaks in Figure 38 should belong to insulin, and insulin diffusion
coefficient at pH 3 at 37 °C is 1.4 x 10’10 m2/s, or 1.4 x 10‘6 cm2/s.
Assuming the insulin molecule is a globular protein, from the StokesEinstein equation (Eq. [4.1]),

kT

The viscosity for a dilute aqueous is approximately equal to that of water, which
is approximately, 1.0 centipoise (cP) or 1.0 * 10*3 Pa s. Thus, the hydrodynamic
radius of insulin

r

(1.38x 10”2 3 AT-1)(310A')
^
1A_9
^
= ------------------- r-------------------------— ----- — = 1.6 x 10 m = \ .6 n m
6;r • (1.0 x 10 Pa • s ) ( l.40x 10 m - s ~ l )
We calculate that the insulin at pH 3 at 2 mg/ml concentration at 37 °C

behaves like a globular protein with a radius of 1.6 nm or with a diameter of 3.2
nm.
Lin, et al. studied the insulin aggregates with pulsed-field gradient nuclear
magnetic resonance spectroscopy at pH 9.4 at 25 °C. 100 They found that at 4
mg/ml, the insulin dimer is the predominant species in the solution, the
hydrodynamic diameters calculated for the dimer is 3.6 nm, and the diffusion
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coefficient detected for the dimer by PFG NMR is 1.38 * 10"6 cm2/s at 25 °C,
which is similar to our result at pH 3.

4.1.2. Using the Analytical Ultracentrifugation to Determine the Insulin
Association State
Human insulin exists in different association states, from monomer to
hexamer, depending on the conditions.101,102,103 In the presence of zinc, the
"normal" state is a hexamer. Zinc ions are not involved in dimer formation but are
involved in the association of dimers to give the hexamer.104 Zinc-free insulin can
have different aggregation levels, six monomers
hexamer, or monomer <-►dimer

tetramer

<-+

*-*■ three

dimers <-»■one

hexamer.105 We would like to

identify the insulin association state under our release condition for the modeling
work; and we used the Analytical Ultracentrifugation to do so.
Analytical Ultracentrifugation (AUC) is a very versatile and powerful
technique for characterizing the solution-state behavior of macromolecules. It
provides a primary method to determine protein molecular weight and size. Using
ultracentrifuge to determine protein molecular weight can be traced back to
1920s.106 The concentration dependence of the molecular weight can provide the
same thermodynamic information as light scattering. The rate of movement of
m olecules provides hydrodynam ic size inform ation. T h e subunit stoichiom etry of

a protein complex can be calculated from the determined molecular weight.
Depending on the quality of the data, this determination can be very accurate; for
example, it can be easily established whether the native conformation of a
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protein is a dimer, trimer or tetramer. Information about the shape and the
conformation of a protein as well as the interaction between macromolecules can
be obtained from the sedimentation and diffusion coefficients obtained from a
sedimentation velocity experiment.
An analytical ultracentrifuge can be viewed as a combination of a
preparative ultracentrifuge and an optical detection system that is capable of
directly measuring the sample concentration inside the centrifuge cell during
sedimentation. The analytical ultracentrifuge at UNH is a Beckman Optima XL-A.
The instrument spins the protein sample at a controlled speed and temperature
while at set times recording the spatial concentration distribution. Depending on
the rotor, the speed may be as high as 60,000 rpm (which is equivalent to
250,000 x g).
One common type of experiment performed in an analytical ultracentrifuge
is sedimentation velocity. Sedimentation velocity is a hydrodynamic technique
and is sensitive to the mass and shape of the macromolecular species. In a
sedimentation velocity experiment, an initially uniform solution is placed in the
cell and a high speed is used to cause rapid sedimentation of solute towards the
cell bottom. This produces a depletion of solute near the top solution meniscus
and the formation of a sharp boundary between the depleted region and the
uniform concentration of sedimenting solute (the plateau) (Figure 39). The rate of
movement of this boundary can be measured, which leads to the determination
of the sedimentation coefficients.
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Figure 39 Schematic representation of the solute concentration
distribution in the centrifuge cell in a sedimentation velocity experiment.

At their isoelectric points, proteins have the lowest solubility; from their
isoelectric points, either raising or lowering the pH, the protein solubility
increases. Insulin does not have good solubility at neutral pH, but the
ultracentrifugation experiment usually requires a protein concentration of 1
mg/ml. Therefore, we prepared a 1 mg/ml insulin in 50 mM citric acid buffer with
100 mM KCI at pH 3.3, which was also the pH value Bentley Pharmaceutical, Inc.
used for their intranasal insulin formulations. Before the ultracentrifugation, the
insulin sample was dialyzed for 10 hours with the pH 3.3 citric acid buffer, which
was used to dilute the insulin solution later on, to make sure the ionic strengths in
the insulin sample and citric acid buffer were the same. Part of the 1 mg/ml
insulin sample was diluted to make a 0.5 mg/ml insulin sample (1:2 dilution) and
a 0.25 mg/ml insulin sample (1:4 dilution). Then we used the Beckman Optima
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XL-A ultracentrifuge at 55,000 rpm and 20 °C to run the sedimentation velocity
experiment.
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Figure 40 Result of insulin sedimentation velocity experiment of analytical
ultracentrifugation at 20 °C. The three curves show the molecular weight
distribution of different insulin species in 1 mg/ml, 0.5 mg/ml (1:2 dilution)
and 0.25 mg/ml (1:4 dilution) insulin buffer solutions at pH 3.3. The buffer
was 50 mM citric acid buffer with 100 mM KCI.

Figure 40 shows the result of the insulin sedimentation velocity
experiment. Due to the complex nature of analytical ultracentrifugation, the result
shall be interpreted carefully. Peaks in sedimentation velocity diagram have no
meanings, and multiple peaks only indicate that the stoichiometry of insulin is
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larger than two, which indicates the presence of higher association states of
insulin than insulin monomer.

4.2. CPE-215® Interaction with Liposome (Membrane)

4.2.1. Intro du ctio n
CPE-215® is a general-purpose membrane permeation enhancer for
protein delivery, which means it is not focusing on specific proteins but
interacting with the lipid phase of membranes in general. CPE-215® is a
hydrophobic molecule, and it interacts with the hydrophobic chains of lipids inside
the membranes.

DPPC

HO

Cholesterol

CPE-215™

Figure 41 Molecular structure of DPPC, Cholesterol and CPE-21511
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Figure 41 shows the structure of the three molecules that we focused on
in the interaction study between CPE-215® and liposome: DPPC was the
phospholipid used to form lipid bilayers and liposomes, cholesterol was inserted
into the DPPC lipid bilayer to change the fluidity of the lipids, CPE-215® was the
membrane permeation enhancer.
Lipid bilayers have different phases. The lamellar gel phase is formed at
low temperature; the molecules are packed tightly together and the acyl chains
are highly ordered, corresponding to the all- t r a n s configuration found in the
structure of lipid crystals. In lamellar liquid crystalline phase, there is twodimensional order, but there is considerable disorder in the acyl chains,
characterized by

gauche

conformation.107 The lipid phase transition between the

lamellar gel and liquid crystalline phases can be thermally induced, and the
phase transition temperature (Tc) is unique to each lipid.

Gel Phase

Liquid Crystalline Phase

Figure 42 Phosphatidyl Choline lipid bilayer phase transition108.

The technique commonly applied to determine the lipid phase transition
temperature is differential scanning calorimetry (DSC).109,110,111,112 It is used to
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monitor and characterize changes in physical state in polymorphic lipids and also
to characterize the perturbations on pure lipids by the interactions with other
materials, such as other lipids, proteins, ions, or small hydrophobic molecules. In
DSC, a sample and inert reference are heated independently to maintain an
identical temperature in each. The endothermic gel-to-liquid crystalline bilayer
transition requires an excess heat over the heat required to maintain the same
temperature in the reference. Differential heat flow is then plotted as a function of
temperature.
Modulated DSC™ (MDSC®) is a new technique which provides not only
the same information as conventional DSC, but also provides unique information
not available from conventional DSC by overcoming most o f the limitations of
conventional DSC.113,114 In MDSC, the same “heat flux” cell design is used;
however, a different heating profile is applied to the sample and reference.
Specifically, a sinusoidal modulation (oscillation) is overlaid on the conventional
linear heating or cooling ramp to yield a profile in which the average sample
temperature continuously changes with time. The heat capacity (reversible)
component of the total heat flow follows the oscillation and can be separated
from the kinetic (non- reversible) component of the total heat flow by Fourier
Transform. Therefore, more accurate phase transition information can be
obtained by MDSC. Furthermore, different from traditional DSC, MDSC can give
increased resolution of transitions without loss of sensitivity.
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4.2.2. Experiment Design
Earlier, we showed that CPE-215® does have a permeation enhancing
effect helping insulin go though lipid bilayers. In absence of the permeation
enhancer, insulin is not likely to go easily through the membrane by itself. As the
membrane permeation enhancer, CPE-215® is supposed to interact with the
membrane in order to facilitate the crossing of insulin. W e wanted to better
understand what happens to the membrane in the presence of CPE-215®.
For a thermal study, the size of the liposome does not need to be narrowly
distributed. In that case, all the liposomes used here were made by bath-type
sonication at 50 °C for 5 minutes, not by extrusion.
CPE-215® is a hydrophobic molecule, and it must interact with the lipid
bilayers in order to act as a permeation enhancer. W e would like to know if CPE215® molecules formed CPE-215® domains inside the lipid bilayers or if they
were evenly distributed in the DPPC liposomes and formed a new kind of
liposome. First, we mixed CPE-215® with DPPC before preparing the liposome,
and then we compared the thermal property of this new DPPC/CPE liposome
with standard DPPC liposome. We also mixed CPE-215® with DPPC and
cholesterol before preparing the liposome and compared the thermal property of
this DPPC/Cholesterol/CPE-215® liposome with the DPPC/Cholesterol
liposomes. For convenience, DPPC liposome was called Liposome D,
DPPC/CPE liposome was called Liposome DC, DPPC/Cholesterol liposome was
called Liposome DH, and DPPC/Cholesterol/CPE-215® liposome was called
Liposome DHC.
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In our insulin release experiment, CPE-215® was added outside of the
liposomes containing insulin. Therefore, in another experiment, we made
Liposome D first and then put CPE-215® together with Liposome D and let the
MDSC perform multiple heating-cooling cycles. Although CPE-215® is
hydrophobic, it still has some minimal solubility in water and its solubility
increases with temperature. With the increase of temperature, more and more
CPE-215® can go into the aqueous phase; while when the temperature cools
down, super-saturated CPE-215® needs to come out of the aqueous phase, and
some will reach the liposomes and enter inside the hydrophobic bilayers. With
multiple cycles of heating and cooling, conceptually we can see the change of
the DPPC liposome thermal properties with CPE-215® slowly diffusing into these
liposomes. CPE-215® has a melting point of 34 °C, which is very close to the
liposome phase transition temperature; in order to reduce such interference, we
used 2:1 (w/w) mixture of CPE-215®/cottonseed oil instead of pure CPE-215®
(Figure 45), which had no thermal transition above 20 °C. W e also run the same
experiment with the Liposome DH.

4.2.3. Experimental Section
The DSC instrument was a Modulated DSC Q100 from TA Instruments,
Inc. Liposomes were made by sonication. Lipids (DPPC, cholesterol, CPE-215®)
were mixed and dissolved in chloroform in 50-ml flask, and then dried at reduced
pressure with a Rotavapor at room temperature for 6 hours to form a lipid film on
the flask wall. The lipid film was hydrated with 10 ml of 50 mM pH 7 phosphate
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buffer at 50 °C and then sonicated for 5 minutes in the bath-type sonicator to
make liposomes. Then the liposomes were concentrated by centrifugation at 900
g for 30 minutes.
The liposomes were sealed in an aluminum pan to measure the liposome
phase transition. After the DSC experiment, a hole was punched in the pan cover
and the pan was kept at 70 °C for 5 hours to let the inside water evaporate,
finally the weight of dry lipid was obtained. Four different liposomes were
characterized for their phase transitions. Table 4 shows the compositions of
these four liposomes.

Table 4. Composition of different liposomes.
Liposome
D

Liposome
DC

Liposome DH

Liposome DHC

Components
weight ratio

N/A

DPPC/CPE

DPPC/Cholesterol

DPPC/Cholesterol/CPE

4:1

4:1

4:1:1

Weight (mg)

5.9

7.5

14.6

12.9

Weight after
drying (mg)

1.5

2.8

3.1

3.9

25%

37%

21%

30%

Lipid
content

The MDSC in our lab is a Modulated DSC Q100 from TA Instruments, Inc.
T h e following MDSC s eq u e n c e w as used for the purpose o f m easuring the lipid

bilayer phase transition temperature:
1. initial temp at 25 °C
2. equilibrium at 5 °C
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3. modulate ± 1 °C/60 sec
4. isotherm for 7 min
5. ramp 5 °C/min to 100 °C
6. isotherm for 2 min

For the multiple heating-cooling experiment of liposomes with CPE215®/cottonseed oil mixture, concentrated liposomes and 2:1 (weight) CPE215®/cottonseed oil mixture were sealed in an aluminum pan and heated from 5
°C to 90 °C for several times. Table 5 shows the different liposomes for the multiheating-cycle experiment.

Table 5. Different liposomes for multiple-heating-cycle experiment.
Liposome D
only

Liposome D with oil

Liposome DH with
oil

CPE/cottonseed
oil 2:1 (w/w) (mg)

N/A

2.9

1.6

Liposome (mg)

23.1

19.2

10.1

4

25

8

# of heating
cycles

The multiple-heating-cooling program is listed below:
1. initial temp at 25 °C
2. equilibrate at 5 °C
3. modulate ± 0.796 °C/60 sec (heat only)
4. isotherm for 6 min
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5. ramp 5 °C/min to 90 °C
6. isotherm for 2 min
7. Repeat from Step 2

In order to see the effect of 2:1 CPE-215®/cottonseed oil on the DPPC
liposome phase transition DSC curve, 11.9 mg 2:1 CPE-215®/cottonseed oil
mixture was sealed in an aluminum pan and the thermal scan from 10 °C to 80
°C (modulation ± 1 °C/60 sec, ramp 5 °C/min) was recorded.

4.2.4. Results and Discussion
The modulated DSC experiments were done for different types of
liposomes: Liposome D (DPPC liposome), Liposome DC (DPPC/CPE-215®
liposome), Liposome DH (DPPC/Cholesterol liposome) and Liposome DHC
(DPPC/Cholesterol/CPE-215® liposome). Figure 43 and 44 showed the resulting
curves. The lipid bilayer phase transition is a reversible, first-order transition;
therefore the figures in this section (Figure 43 to Figure 51) show only the
reversible heat flow by removing the kinetic (non- reversible) component from the
total heat flow.
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Figure 43 DSC of Liposome D (DPPC liposome) and Liposome DC
(DPPC/CPE-215® liposome) (exothermal up).

The DSC of Liposome D showed a phase transition temperature at 42 °C
(we conveniently took the peak temperature as the phase transition
temperature), which was similar to the literature value.108 The phase transition of
highly purified DPPC should be sharp, but in Figure 43, the phase transition peak
seemed a little broad, which may be due to minor impurities in the lipid.
The reversible heat flow of Liposome DC (4:1 (w/w) DPPC/CPE-215®)
show ed one broad endotherm ic p e ak with th e p e a k v alu e of 3 4 °C (in our

Liposome DC, the molar ratio of DPPC: CPE-215® was 1.3). Compared with the
reversible heat flow curve of Liposome D, the phase transition temperature of
Liposome D was lowered by incorporating CPE-215® with DPPC in the
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liposomes. Since there was no endothermic peak at 42 °C in the reversible heat
flow curve of Liposome DC, there should be no DPPC domains in Liposome DC,
or at least the gathering of DPPC in Liposome DC was not significant enough to
initiate an endothermic peak in the DSC heat flow curve. As to the question of
whether CPE-215® formed domains in Liposome DC, unfortunately this could not
be answered based on Figure 44 alone because the CPE-215® itself has a
melting point of 34 °C, the same temperature as the phase transition temperature
of Liposome DC. Even if there were CPE-215® domains inside, the CPE-215®
melting peak would be covered by the broad liposome phase transition.
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Figure 44 DSC of Liposome DH (DPPC/Cholesterol liposome) and
Liposome DHC (DPPC/Cholesterol/CPE liposome) (exothermal up).
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Cholesterol is a common lipid in natural membranes. Therefore, we also
used Liposome DH (4:1 (w/w) DPPC/cholesterol) as the membrane model and
incorporated CPE-215® inside to see if the phase transition temperature was also
lowered after the addition of CPE-215®. Figure 44 showed the modulated DSC
reversible heat flow curves of Liposome DH and Liposome DHC (4:1:1 (w/w/w)
DPPC/cholesterol/CPE-215®), and the phase transition temperatures were 46 °C
and 37 °C respectively. Cholesterol made the phase transition of DPPC liposome
broader an increased its average value, while CPE-215® lowered the liposome
phase transition temperature. Figure 44 also showed that there were no CPE215® domains in the final liposome, CPE-215® and cholesterol were evenly
distributed in the DPPC liposome and formed a liposome with new thermal
property.
Among the phase transition peaks of Liposome D, Liposome DC and
Liposome DH, the phase transition of Liposome DH was the broadest, the phase
transition of Liposome D was the narrowest, while the broadness of the phase
transition peak of Liposome DC was intermediate. This might be due to the
structure of cholesterol and CPE-215® molecules. Cholesterol is a compact, rigid
hydrophobic entity with a polar hydroxyl group. With cholesterol in the liposome
bilayer, it is difficult for the DPPC lipid to pack the hydrocarbon chains next to the
rigid sterol moiety. In the liquid crystalline state, the sterol results in
conformational constraints on the phospholipid chain, whereas in the gel state
the sterol inhibits optimal packing of the all- t r a n s chain configuration. The result
is that lipid-cholesterol mixtures behave as intermediate between the gel and
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liquid crystalline states of the pure phospholipid, which explains the broadness of
the phase transition of Liposome DH. Basically, cholesterol acts as a “spacer”
and reduces the attractive forces between the lipid hydrocarbon chains.
Compared to cholesterol, CPE-215® is a more flexible lactone

of a

16-membered

ring and can cooperate better with phospholipid hydrocarbon chains. In the gel
phase, the CPE-215® can change its conformation so that the phospholipid
hydrocarbon chains can pack mostly as

tra n s

conformation; in the liquid

crystalline phase, CPE-215® can also change its conformation to minimize the
interference with the

gauche

packing of the phospholipid hydrocarbon chains.

This can explain why the phase transition of DPPC/CPE-215® liposome is
narrower than that of Liposome DH. Cholesterol’s rigidity and CPE-215®’s
flexibility may also account for the phase transition temperature change of the
liposomes.
In our insulin release experiments, we started with DPPC (or
DPPC/Cholesterol) liposomes and CPE-215® was added outside of liposomes;
with CPE-215® continuously contacted with liposomes and went into the lipid
bilayer, Liposome D (or DH) became Liposome DC (or DHC). From Figure 44
and 44, we only learned that the phase transition temperature of Liposome DC
(4:1 (w/w) DPPC/CPE-215®) was lower than that of Liposome D, but we would
also like to know how the DPPC liposome phase transition temperature changed
while CPE-215® was gradually incorporated inside (Did the phase transition
temperature decrease continuously? Or did the phase transition temperatures
not change, just the old peak decreasing and the new peak increasing?) It is
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similar to the situation that after we discovered the starting point A and the end
point B, we would also like to know how to get to B from A.
In order to make CPE-215® go into the liposome gradually, we planed to
seal the Liposome D with CPE-215® inside a 50-pl aluminum pan with a cover
and heat it from 5 °C to 90 °C for multiple cycles with the modulated DSC.
Although CPE-215® is hydrophobic and has little solubility in water, its solubility
can increase with temperature. With the increase of temperature, more and more
CPE-215® can go into the aqueous phase; while when the temperature cools
down, super-saturated CPE-215® needs to get out of the aqueous phase, and
some will find the liposomes and go inside of bilayers. With multiple cycles of
heating and cooling, CPE-215® will gradually transport into the lipid bilayers, and
we will monitor this continuous change by the modulated DSC. In this
experiment, we did not want the sealed mixture to have any thermal phase
change, except the liposome phase transition itself, from 20 °C to 60 °C. Due to
the melting point of CPE-215® at 34 °C, we could not use the pure CPE-215®
with Liposome D. W e found that the mixture of 2:1 (w/w) CPE-215®/cottonseed
oil did not have thermal phase change from 20 °C to 60 °C (Figure 45), so that
we used 2:1 CPE-215®/cottonseed oil instead.
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Figure 45 DSC of 2:1 (w/w) CPE-215®: cottonseed oil (exothermal up).
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Figure 46 was the reversible heat flow of modulated DSC of four heating
cycles of Liposome D. This showed that the phase transition of Liposome D was
reversible, transition peak size and position did not change with the number of
heating cycles if there was no outside interference. In other words, if the lipid
bilayer structure/composition did not change, the phase transition peak size and
temperature would not change; if the phase transition size and temperature
changed, then there must be changes in the lipid bilayer structure or
composition.
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Figure 47 25 heating cycles of Liposome D (DPPC liposome) with CPE215®/cottonseed oil mixture.

Figure 47 shows the result of the multiple heating and cooling of Liposome
D and 2:1 (w/w) CPE-215®/cottonseed oil mixture. The reduction of the heat of
the phase transition and the decrease of the transition temperature are
interpreted to be due to CPE-215® gradually diffusing inside of DPPC lipid
bilayers. Since there was no endothermic peak increasing around 34 °C (mp of
CPE-215®) and only the whole liposome phase transition peak shifted to low
temperature during the cyclic process, we concluded that CPE-215® was evenly
distributed in liposomes from the beginning, which was thermodynamically
favored. If we looked at Figure 47 in detail, we could find that with the number of
heating cycles increasing, the starting temperature of the phase transition
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decreased, while the ending temperature of the phase transition almost did not
change. This meant with more and more CPE-215® gradually inserted into the
DPPC liposome, lower temperature was required to make the system deviate
from ordered packing state, but the same high temperature was still needed to
get the whole system away from ordered packing. CPE-215® is a small flexible
molecule, its gradual insertion into the DPPC lipid bilayer disturbed the

a \\- tr a n s

ordered packing of phospholipid hydrocarbon chains in the gel state, which
resulted in lower starting temperature of the liposome phase transition. However,
since the majority was still DPPC lipid, each time the same high temperature was
still needed to get all the DPPC chains in the

gauche

conformation to reach the

liquid crystalline state.
Figure 48 showed how the liposome phase transition temperature
changed with the number of heating cycles, which decreased almost linearly at
the beginning and reached a plateau in the end.
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Figure 48 Change of phase transition temperature of Liposome D with the
number of heating cycles.

In order to see if CPE-215® could only reduce the phase transition
temperature of Liposome D, we did the same multi-heating-cycle experiment with
Liposome DH. Figure 49 was the DSC result, which also showed that the phase
transition temperature of Liposome DH decreased with continuous insertion of
CPE-215®. Although the phase transition for Liposome DH was very broad, the
peak shift with number of heating cycles was still quite noticeable. We took the
lowest point of the curve as the phase transition temperature. Figure 50 showed
the phase transition temperature decreased with number of heating cycles. The
decrease was almost linear with the number of heating cycles.
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Figure 49 Eight heating cycles of Liposome DH (DPPC/Cholesterol
liposome) with CPE-215®/cottonseed oil mixture (exothermal up).
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W e also looked at the enthalpy change of liposomes during the lipid
bilayer phase transitions. Since the phase transitions of cholesterol-containing
liposomes are too broad, it is hard to tell the starting and ending points of those
transitions and accurately obtain the enthalpy change; in that case, here we only
discuss the phase transition of the DPPC liposomes. According to the thermal
data of Figure 43, the enthalpy change during the Liposome D phase transition is
37 kJ/mol, which is similar to the literature value.108 However, the enthalpy
change in the phase transition of Liposome DC is only 20 kJ/mol, assuming only
DPPC molecules in the liposomes accounted for the enthalpy change, not CPE-
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215®. The big difference between the enthalpy change of Liposome D and
Liposome DC can be explained from the different molecular conformation of
DPPC molecules in those two liposomes. As we have discussed before, during
the phase transition of Liposome D from lamellar gel phase to lamellar liquid
crystalline phase, the conformation of the acyl chains of DPPC molecules are
changed from all- t r a n s to

gauche,

and the enthalpy change is related to the

energy needed to convert the DPPC acyl chains from the highly ordered, low
energy level all- t r a n s conformation to the

gauche

conformation. In Liposome DC,

due to the insertion of CPE-215® molecules in the DPPC lipid bilayer, not all the
DPPC acyl chains are packed in

tra n s

conformation in the lamellar gel phase,

which increases the energy level of the gel phase of Liposome DC and results in
less enthalpy change during the phase transition.
Thermal data from Figure 47 further supported the above explanation.
After calculation, we found that with CPE-215® diffusing into the DPPC
liposomes, the Liposome D phase transition enthalpy change decreased
gradually from 37 kJ/mol to 22 kJ/mol after 25 cycles of heating and cooling
(Figure 51).
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Figure 51 Change of phase transition AH of DPPC in Liposome D (DPPC
liposome) with CPE-215® insertion.

Table 6 DSC study summary table
To (°C)

Transition width

AH of DPPC
(kJ/mol)

DPPC liposome

42

Narrow

37

DPPC/CPE-215®
liposome

34

Broad

20

DPPC/Cholesterol
liposome

46

Very road

N/A

DPPC/Cholesterol/CPE215® liposome

37

Broad

N/A
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4.2.5. Conclusion
With the help of the powerful modulated DSC technique, we carried out a
series of liposome phase transition studies. We found that adding CPE-215® into
the lipid bilayer could reduce the phase transition temperature of liposomes.
Adding both CPE-215® and cholesterol into the lipid bilayer can broaden the
phase transition of DPPC liposomes, but CPE-215® has less peak broadening
effect than cholesterol, which may be due to the rigidity of cholesterol and the
flexibility of CPE-215®. When inserted into the lipid bilayers, CPE-215® was
evenly distributed in the bilayers. With CPE-215® gradually inserted into the lipid
bilayers, the liposome phase transition temperature was gradually shifted to
lower temperatures, and the liposome phase transition enthalpy change also
decreased gradually.

4.3. Insulin Interaction with Liposome (Membrane)
Depending on the surface properties and the distribution of hydrophilic or
hydrophobic regions on the surface, different proteins interact with liposomes in
different ways. Usually there are three types of interaction between
protein/peptide and lipid bilayer: adsorption, insertion and penetration (Figure
52).
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Protein Adsorption

Protein Insertion

Protein Penetration

Figure 52 The interaction modes between protein and lipid bilayer
membrane.

Understanding the interaction between insulin and liposomes is important
to our mechanism study of insulin release from liposomes and permeation
enhancing effect of CPE-215®. Zhang, et al. studied the interaction between
insulin and liposome by fluorescence spectra and microcalorimetry methods.115
They found that the interaction between insulin and liposome was weak; there
was no protein insertion or penetration, probably only weak adsorption; the heat
effect of the interaction AH= -1.98 kcal/mol, which indicates weak non-covalent
binding.
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4.3.1. Centrifugal Extraction to Determine the Insulin Adsorption Coefficient
on Membrane
From our experience in handling insulin molecules during the release
experiments, we learned that insulin molecules can adsorb on the surface of
liposomes; otherwise, we would not have needed to perform the multiple
centrifugal extractions to ensure the outside surface of liposomes was insulinfree before the release experiments.
Each of the 20 amino acids can be distinguished by the R-group
substitution on the a-carbon atom. There are two broad classes of amino acids
based upon whether the R-group is hydrophobic or hydrophilic. Usually the
hydrophilic amino acids tend to interact with the aqueous environment and are
often found on the exterior surface of proteins, but some hydrophobic amino
acids also exist on the exterior surface, which accounts for the hydrophilic
regions and hydrophobic regions on the protein surface. Under the hydrophilic
surface, liposomes have the hydrophobic layer to isolate the inside from outside
environment. Protein can adsorb on the liposome surface by letting its hydrophilic
regions contact the liposome hydrophilic layer.
Our insulin adsorption isotherm is based on three assumptions: adsorption
cannot proceed beyond monolayer coverage; all liposome surface sites are
equivalent and can accommodate, at most, one adsorbed protein; the ability of a
protein molecule to adsorb at a given site is independent of the occupation of
neighboring sites. As one can see, our isotherm is similar to a Langmuir
isotherm.116
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The dynamic equation is:
Rate of adsorption
where

0

Insulin + Surface <-> Insulin-Surface

V a - k xC ( 1 - 0 )

is the fractional liposome surface coverage,

ki

is the insulin adsorption

rate constant, C is the insulin solution concentration.
Rate of desorption
where

k.i

V d - k _ x6

is the insulin desorption rate constant.

At equilibrium, the rate of adsorption is equal to the rate of desorption.
Then

k xC { \ - 6 ) =

k

k_xe

[4.5]

_ K

with ^ - ,

k_ i

1+

K C

[4.6]

'

We carried out a precise centrifugal extraction experiment to determine
the insulin adsorption coefficient,

K,

on the liposome surface. After the normal

procedure of making 400 nm 4:1 (w/w) DPPC/Cholesterol liposomes in insulin
solution at pH 7, we performed the centrifugal extraction at 4 °C. We used the
DYNAC centrifuge at 2000 rpm, which was slow compared to the ultracentrifuge,
but fair enough to concentrate the liposomes to the bottom of the tube. We
allowed 1 hour for the insulin desorption and adsorption to reach equilibrium for
each centrifugal extraction process. We wanted to see the insulin adsorption
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equilibrium at 37 °C, but the lipid bilayer surface is not a solid sphere, and its
fluidity depends on its temperature. If we perform the centrifugal extraction at
high temperature, for example 37 °C, not only could the liposomes break during
the centrifugation, but the inside insulin could come out to interfere with the
outside insulin concentration. In that case, this experiment had to be carried out
at low temperature, to ensure the hardness of the liposome sphere and minimize
the leakage of insulin from inside of liposomes.
Following each centrifugal extraction, we recorded the volume of insulin
solution in the centrifuge tube (excluding the volume of liposomes), and used
fluorescence to detect the insulin concentration of the supernatant (before the
fluorescence measurement, centrifuge filtration with 50 KDa MWCO membrane
filters was used to separate insulin solution from liposomes); then we recorded
the volume of supernatant that we took out and the volume of fresh buffer we
added in. W e used the calibration curve to convert the fluorescence signal to
insulin concentration.
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Figure 53 The fluorescence signal of the supernatant was measured after
each centrifugal extraction for 8 times. Note the fluorescence signal is on
a log scale.

Figure 53 shows the decrease of fluorescence signal of the supernatant with the
increase of centrifugal extraction times. Since the decrease in the signal was so
drastic for the first couple extractions, the fluorescence signal is shown on a log
scale, which indicates that the insulin adsorption on the liposome surface is not a
strong interaction. After 3 extractions, the fluorescence signal was near that of
the background.
After the ith centrifugal extraction, the insulin concentration, C,, is the result
of dilution and insulin desorption from the liposomes. Therefore, the remaining
solution volume (excluding the liposome volume) after removing the supernatant,
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]/ „ ,

and the final solution volume after adding fresh buffer,

V,,

are two important

parameters. Then according to the mass balance
Cl_xVri+ a 0 i_x= C iVl + a e i

[4.7]

where a is the amount of insulin adsorbed on the liposome surface when
0=100%.

Table 7 Centrifugal extraction data
/
0
1
2
3

C, (mg/ml)
0.11
3.78 x 10'*
2.64 x 10'4
5.39 x 10"&

(ml)
N/A
0.33
0.11
0.17

(ml)
N/A
11.40
11.28
11.38

Vri

Vi

Table 7 listed the information from the centrifugal extraction experiment,
which were used to calculate the adsorption coefficient,

K.

From the equations of
CqV,.j

+

u0o —CXVX+ <20j

CxVr2 + adx = C2V2 + a02

1+

KC0

1

1+

KCX

2

1+ k c

4

2
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we can calculate the values of K ,

a,

0*. 02, 03-

We solved this system of equations and obtained two possible
mathematical solutions, one was

K -

97 ml/mg, the other was

ml/mg. Based on the solutions we got, when
0.268, 02 = 0.025, a = 0.0105 mg; when
=

K =

K -

K

= 7.13 * 105

97 ml/mg, 0o = 0.914,

9i =

7.13 *1 0 5 ml/mg, 0O= 0.999987,

61

0.99963, 02 = 0.9947, a = 18.99 mg. However, the total amount of insulin we

put into the system when we prepared the liposomes, both inside and outside of
liposomes, was less than 1.4 mg of insulin; hence, it is impossible to have 18.99
mg of insulin adsorbed on the liposome surface. Therefore,

K

= 7.13 *1 0 5 ml/mg

is only a mathematical solution, with no physical reality, and was discarded.

K

=

97 ml/mg is the reasonable equilibrium constant for insulin to adsorb on a
DPPC/Cholesterol liposome membrane.
Our calculation showed that if the liposome surface was 100% covered by
insulin, the amount of insulin on the liposomes surface was 0.0105 mg. In our
experiment, after the liposome extrusion process, there were 0.067 g of DPPC
and 0.017 g cholesterol in the liposomes. Since cholesterol has a much smaller
hydrophilic group than DPPC, we only used the DPPC amount to estimate the
liposome surface area. Since the liposomes we made were 400 nm large
unilamellar liposomes, we assumed there was no curvature effect and the overall
surface area of liposomes was equal to the one side surface of one planar lipid
bilayer. A phosphatidylcholine’s hydrophilic head group has an average surface
area of 50 A2,117 the total liposome surface in our experiment S = 0.067 g + 734
g/mol + 2 x 6.02 * 1023 /mol * 50 A2 = 1.37 x 1021 A2. Therefore, when the
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liposome surface was 100% covered by insulin (0 = 1), the area occupied by
each insulin molecule was 1.37 * 1021 A2 + (0.0105 x 10'3 g + 5800 g/mol * 6.02
x 1023 /mol) = 1.26 x 1o6 A2, which is similar to a square of 112 nm x 112 nm. As
we know, the diameter of insulin monomer is less than 3 nm; therefore, even at
100% coverage, the liposome surface was loosely occupied by insulin molecules,
which is another proof of weak interaction. When 0 = 1, on the inner surface of
each 400 nm liposome, the average number of insulin monomer is 3.14 x (4000

A)2 + 1.26 x 10®A2 = 40; most likely, insulin would exist as dimer when 0 = 1,
then there would be 20 insulin dimer adsorbed on the inner surface of each 400
nm liposome. This particularly low number of adsorbed insulin molecules
indicates that insulin has a very low affinity for the outside of the lipid bilayer.
All these results confirmed that there is interaction between insulin and
liposome, but such interaction is weak, most likely through electrostatic
interaction.

4.3.2. ITC Experiment of Insulin Titration on Liposome
Isothermal Titration Calorimetry (ITC) is a thermodynamic technique for
monitoring any chemical reaction initiated by the addition of a binding
component, and has become a method of choice for characterizing biomolecular
interactions.118,119 When substances bind, heat is either generated or absorbed.
Measurement of this heat allows accurate determination of binding constants,
reaction stoichiometry, enthalpy and entropy, thereby providing a complete
thermodynamic profile of the molecular interaction in a single experiment.
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Injection of a ligand into the target molecule (which is accommodated in the
calorimeter cell) will result in an endothermic, or exothermic, enthalpic event
which will be observed as a heat pulse.
When we used ITC to study the insulin adsorption on liposome surface,
insulin was the titrating ligand and the liposome was the target substance. Since
the interaction was expected to be weak, insulin solution with high concentration
was used to obtain enough signal strength. We prepared 5 mg/ml (0.86 mM)
insulin solution and two kinds of liposomes with the lipid content of 5 mg/ml at pH
3.1 in 30mM citrate buffer to study the interaction of insulin with liposomes, i.e.
400 nm 6:1.5:1 (weight) DPPC/Cholesterol/CPE-215® unilamellar liposome and
400 nm 4:1 (weight) DPPC/Cholesterol unilamellar liposome. W e also sealed
insulin solution and liposome solutions into dialysis tubes and put them into the
pH3.1 30 mM citrate buffer overnight to make sure they all had the same pH and
ionic strength. The dialysis membrane had a molecular weight cutoff of 3500 to
make sure insulin and liposome can not pass through.
MicroCal, Inc. kindly agreed to perform the titration experiment for us
using their VP-ITC at 37 °C. Besides two liposome sample titrations, a control run
was also carried out, i.e. using insulin to titrate pH 3.1 citrate buffer.
Before the titration, the liposomes were placed in the calorimeter cell
(1.428 ml cell volume) at 37 °C. The insulin solution was loaded in the syringe,
and the titration program adjusted for 10 pl/injection (2 pi for 1st injection), 3.5 min
interval between injections, 20 sec per injection.
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Figure 54 The VP-ITC raw data of two liposome sample titrations and one
control run (endo up). Two liposome samples (400 nm 6:1.5:1 (weight)
DPPC/Cholesterol/CPE-215 unilamellar liposome and 400 nm 4:1
(weight) DPPC/Cholesterol unilamellar liposome) were titrated by insulin
(5 mg/ml; 0.86 mM) in 30 mM pH 3.1 citrate buffer at 37 °C. 10 pl/injection
(2 pi for 1st injection), 3.5 min interval between injections, 20 sec per
injection, 280 rpm stirring.

Figure 54 shows the ITC raw data for two sample titrations and one
control run. The heat effects for the control (upper curve) were endothermic and
its magnitude decreased quite rapidly as the titration proceeded. Near the end of
the titration, the heat effects became very small and constant. These data
appeared to be the result of the heat of dilution of a concentrated insulin solution
(0.86 mM) injected into a buffer. Due to our dialysis treatment of the samples
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before the titration, the large endothermic heat observed for the control run could
not be due to pH mismatch. Additionally, a likely source for these endothermic
heat effects is the insulin dimer to monomer dissociation when the insulin
solution was diluted into the buffer. The heat effects for the two liposome sample
titrations are very similar to that of the control, though their endothermic heat
effects were slightly smaller than those of the control due to the weak binding of
insulin to the liposome surface.
The integrated heats for three titration experiments are shown in Figure 55
after normalizing by the insulin concentration (using 0.86 mM). The differences in
the integrated heats between the liposome samples and the control are small. It
appears that the sample of DPPC/Cholesterol/CPE-215® liposome has a slight
larger exothermic net heat than that of DPPC/Cholesterol sample.
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Figure 55 VP-ITC heat data after auto baseline integration, normalized on
insulin concentration (0.86 mM). 400 nm 6 :1.5:1 (weight)
DPPC/Cholesterol/CPE-215® unilamellar liposome and 400 nm 4:1
(weight) DPPC/Cholesterol unilamellar liposome) were titrated by insulin
(5 mg/ml; 0.86 mM) in 30 mM pH 3.1 citrate buffer at 37 °C. 10 pl/injection
(2 pi for 1st injection), 3.5 min interval between injections, 20 sec per
injection, 280 rpm stirring, x, control titration; • , DPPC/Cholesterol
liposome; □, DPPC/Cholesterol/CPE-215® liposome. Positive heat value
means endothermal process.
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Figure 56 VP-ITC heat data after the sample runs subtracted the control run
point by point. •, DPPC/Cholesterol liposome; □, DPPC/Cholesterol/CPE^IS*
liposome. Negative heat value means exothermal process.

In order to clearly show the net heat effects of insulin adsorption on
different liposome surfaces, the heat data of the control run were subtracted from
that of liposome samples point by point, and Figure 56 shows the subtraction
results. In Figure 56, we can see that DPPC/Cholesterol/CPE-215® liposomes
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have a larger exothermic net heat than DPPC/Cholesterol liposomes. The net
exothermic heat from insulin adsorption on DPPC/Cholesterol/CPE-215®
liposomes is almost twice that of DPPC/Cholesterol liposomes, which clearly
indicates a higher affinity of insulin to the surface of DPPC/Cholesterol/CPE-215®
liposome than to the surface of DPPC/Cholesterol liposome.

4.4. Mechanistic Hypothesis for the Insulin Release from Liposome

4.4.1. Diffusion through Lipid Bilayer Membrane
Since the permeability of lipid bilayer membranes to small molecules is a
well-studied field,120,121 at the beginning of our mechanistic study of permeability
of insulin through lipid bilayers, we started by testing the mechanism of small
molecules crossing lipid bilayer membrane first.
The ability of a small solute molecule to cross the lipid membrane is
quantified by its permeability coefficient. For a molecule to cross the bilayer, it
must (1) enter the membrane, overcoming any interfacial resistance or free
energy barrier to do this, (2) diffuse across the bilayer, and (3) exit the membrane
on the opposite side, again, overcoming any possible interfacial resistance. Any
of these steps could, in principle, be rate limiting. The permeability of most
nonelectrolytes through lipid bilayer membranes can be successfully analyzed by
the

s o lu b ilit y - d if f u s io n

model, which makes the assumption that the rate-limiting

step is the diffusion within the lipid bilayer and that interfacial barriers for
membrane entry and exit are negligible. This allows one to assume a rapid
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partition equilibrium between the aqueous and membrane phases (step 1 and 3
in Figure 57). The partition coefficient,

K

= i £ n = i s

'

[C?]

K p,

is defined by

i

[C f]

(1)

1 1

(2)

(3)

Figure 57 Simple schematic representation of the solute concentration
change while crossing a lipid bilayer membrane according to the solubilitydiffusion model. The solute concentrations at locations in the membrane
(m) and aqueous (aq) phase are indicated. The numbers at the bottom
refer to the steps required for a solute to cross the membrane from left to
right.

The permeability coefficient, P, in terms of the net flux, from side 1 to side
2, of solute across a m e m b ran e of thickness of, is defined by

flux = P - { C “q - C a2q)

[4.9]

This same flux can be expressed in terms of the diffusion coefficient describing
the flux of solute within the membrane,

D m,

using Fick’s first law.
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[4.10]
where the concentration gradient is assumed to be linear across the bilayer.
Substituting from equation 4.8 into equation 4.10 yields

[4.11]

p

Comparing equation 4.9 and 4.11 gives

The permeability coefficient is a product of the partition coefficient and diffusion
coefficient within the membrane, divided by the width of the membrane.
We have already obtained the insulin diffusion coefficient in aqueous
solution from NMR, which is 1.4 * 10'6 cm2/s at 37 °C for insulin dimer. Since the
hydrophobic layer of the bilayer membrane is made of long hydrocarbon chains,
we tried to estimate

Dm

from the insulin diffusion coefficient in decane. Due to the

extremely low solubility of insulin in decane, it is very hard to obtain the insulin
diffusion coefficient in decane experimentally. According to Stokes-Einstein
equation (equation 4.1), the diffusion coefficient is determined by temperature,
the viscosity of the liquid and the hydrodynamic radius of the molecule. The
viscosity of decane at 20 °C is 0.92 cP, which is very similar to that of water at 20
°C (1 cP). In that case, at the same temperature, the insulin diffusion coefficient
in decane should be very similar to that in water, or at least in the same
magnitude of 10'6 cm2/s. However, the hydrocarbon chains of the lipids in the
lipid bilayer are lined up and orderly packed, which is not like the free decane
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molecules. From insulin adsorption on the membrane surface to insulin insertion
into the membrane, the movement of insulin is associated with the lateral
movement of lipids molecules. Therefore, the lateral diffusion (diffusion is
restricted to two dimensions) coefficient of lipid should also be considered.122 The
lateral diffusion coefficient in unilamellar vesicles of DPPC at 50°C was
measured to be 8 * 10"8 cm2/s .123 According to our DSC data of DPPC liposomes
(Figure 43), 37 °C and 50 °C are all in the phase transition range, therefore, the
lateral diffusion coefficient in unilamellar vesicles of DPPC at 37°C should be of
the order of 10'8 cm2/s. We would use 10'8 cm2/s to estimate the insulin diffusion
coefficient in DPPC lipid bilayer at 37 °C.
The thickness of one lipid bilayer is about 4 -5 nm. If we assume the
insulin permeation through lipid bilayer is a diffusion-controlled process like the
small nonelectrolytes, then according to the relation between the diffusion
coefficient and the mean-square displacement, <x2>,
< * 2>

D

It

[4.13]

’

the time required for insulin molecule to cross the lipid bilayer would be

< = (j^>= J 4 x l O - W
2D

m

2x10

^

cm ■j

This calculation indicates that once insulin is in the lipid bilayer, it takes
almost no time for insulin to cross the membrane, but our insulin release
experiment data did not show such a fast insulin release rate. Therefore, we can
see diffusion is not the rate-limiting step for the insulin release from liposome,
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and we cannot ignore the large electric potential energy increase caused by
protein surface charges in the bilayer membrane. The partition coefficient,
(Equation[4.8]), of insulin in lipid bilayer must be very low. With both low
D m,

Kp

K p and

it is not surprising that insulin has low permeability in lipid bilayers (Equation

[4.12]).
Insulin in water is stabilized by the favorable interaction of the water
dipoles, the hydration energy. Moving insulin between media of different
dielectric constants, e.g., from an aqueous phase to the bilayer membrane
interior, is unfavorable because of the loss of this hydration energy.

4.4.2. The Role of CPE-215® as a Membrane Permeation Enhancer
From our release experiments, we know that at 37 °C, insulin has a small
leakage rate from liposomes even without the addition of CPE-215®; the addition
of CPE-215® greatly increased the insulin release rate from liposomes.
Therefore, our mechanism hypothesis should at least explain these two
phenomena.
Liposome leakage has been studied for decades. There are several
competing theories, focusing on defects in the packing order of the bilayer.
These defects are postulated to form spontaneously, like fluctuating holes124, or
possibly along boundaries between coexisting lipid gel and liquid crystalline
phases125. Liposome leakage is maximal at the transition temperature between
the gel and liquid crystalline phases126, which indicates that the leakage is not
due to a simple increase in molecular motion at higher temperatures, but is due
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to a transient structural disorder of the lipid packing induced by the phase
separation.
Based on this information, we propose that the rate-limiting step for insulin
release from liposome is the probability for an insulin molecule to find a
appropriate defect in the lipid bilayer to cross the membrane, and the rate of
insulin release,

V,

can be expressed

asV

oc

P. • P d t

where P,is the probability of

insulin molecules adsorbed on the lipid bilayer surface, Pd is the probability of
defects in the lipid bilayer.
Our ITC experimental data show a larger net insulin adsorption exothermic
heat on DPPC/Cholesterol/CPE-215® liposome surface than on
DPPC/Cholesterol liposome surface, which indicates a higher affinity and larger
adsorption coefficient of insulin on the surface of DPPC/Cholesterol/CPE-215®
liposome than on the surface of DPPC/Cholesterol liposome. Therefore, with the
addition of CPE-215® in the lipid bilayer, more insulin can be adsorbed on the
liposome surface, that is, the addition of CPE-215® can increase P,.
Although the hydrophobic CPE-215® likes to go into the interior
hydrophobic region of the bilayer membrane, there is a hydrophilic layer at the
outmost surface of liposome and CPE-215® has to cross that layer first to go
inside of the bilayer. It is clear that the bilayer is a remarkably good barrier
against both hydrophilic and hydrophobic molecules. However, the defects in the
liposome surface are perfect places for CPE-215® to enter the bilayer. Once
CPE-215® molecules go into the defect, they stabilize the defect and make a
hydrophobic region on the liposome surface attract more CPE-215® to make
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larger defect. As a result, CPE-215® can increase

P d.

However, the size of the

stabilized defect is limited by the energy cost associated with the creation of a
large CPE-215®/water interface.
The above analysis shows that CPE-215® has positive effect on the two
major factors in the rate-limiting step of insulin release. That is our rational on
how CPE-215® can facilitate the insulin release from liposomes.
Compared to the totally hydrophobic hydrocarbon chains of the lipids,
CPE-215® has a better affinity to the insulin molecule due to its polar ester group.
Figure 58 shows the insulin dimer surface property region distribution. The insulin
dimer structure was obtained from RCSB Protein Data Bank, and was displayed
by Swiss-PdbViewer. Those regions are determined by the property of amino
acid side groups: the polar regions are red, the non-polar regions are blue, the
acidic/basic regions are yellow. The non-polar regions are ready to be in the
hydrophobic environment; although the polar regions are not as good as the non
polar regions in the hydrophobic environment, they are much better than the
acidic/basic regions; the acidic/basic regions do not want to stay in the
hydrophobic environment at all, because they can lose the hydration energy once
they move from hydrophilic phase to the hydrophobic phase within the lipid
bilayer.
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Figure 58 Insulin dimer surface property region distribution: the polar
regions are red, the non-polar regions are blue, the acidic/basic regions
are yellow.

When insulin dimer enters the defect in the liposome, the CPE-215®
molecules in the defect can cover the non-polar and polar regions on the dimer
surface, some may even cover the acid/basic regions because insulin prefers
CPE-215® to hydrocarbon chains of lipid anyway. Then the whole insulin dimer
molecule can be shielded by CPE-215® molecules and cross the bilayer with less
energy barrier. This is another possible role of CPE-215® as a membrane
permeation enhancer, though this may not be the major facilitating effect of CPE215® on the insulin release from liposome process.
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4.4.3. Proposed Hypothesis for the Whole Insulin Release Process
From our release data with different formulations and different conditions,
we found one similar phenomenon— different formulations can initiate different
initial release rates, but high insulin release rates only appeared at early release
time, later on all the release rates were similar and independent of enhancer
formulation. Figure 59 is an example of this phenomenon that has been
systematically observed.
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Figure 59 Insulin release from a DPPC/Cholesterol liposome at 37 °C

Figure 59 shows the insulin release from a DPPC/cholesterol (4:1 w/w)
liposome at 37 °C. In this experiment, three release tubes contained the same
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amount of DPPC/cholesterol (4:1 w/w) liposomes. One tube was used as blank
control, one tube received a CPE-215®/cottonseed oil (3:1 w/w) mixture, and the
other received a CPE-215®/cottonseed oil (3:1 w/w) mixture with p-cyclodextrin
(1%). The release data showed that the insulin release rate of the blank control
almost remained the same throughout the whole experiment, which showed the
intrinsic leakage rate of a DPPC/cholesterol liposome. After the addition of CPE215®/cottonseed oil mixture, the release rate was about twice the release rate of
the blank control at the beginning, three hours later, the release rate began to
slow down, and finally the release rate was equal to the one of the blank control.
The formulation containing P-cyclodextrin really boosted the initial insulin release
rate (about 8 times from the blank control rate, and 4 times from the formulation
containing only CPE-215® and cottonseed oil). Later this rate also slowed down
to equate to the rate of blank control release. In Figure 59, we divided the release
data into three phases: Phase I, when the high initial release rates occur; Phase
II, when the release rates begin to decrease; Phase III, when the release rates
are all equal to the rate of the blank control.
Figure 60 shows a molecular level illustration of our proposed hypothesis
for the whole insulin release process with CPE-215®. According to our DSC data
(Figure 44), 37 °C is in the phase transition range of DPPC/cholesterol liposome,
and there are defects existing in liposome. Due to the reason we discussed
earlier, the oil mixture prefers being inserted into the defects of lipid bilayer. Once
CPE-215® molecules go into the defect, they stabilize the defect and make a
hydrophobic region on the liposome surface to attract more CPE-215® to form a
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domain of CPE-215®, probably a few nanometers in diameter, which is not
detectable by MDSC. As a result, high stress is generated at the outer surface of
the liposome, and a transient CPE-215® “pore” is formed to facilitate the protein
transport through the membrane. That is Phase I in Figure 59 and 60.

Defect

CFO O

Liposome
Low insulin leak rate

T=0

High insulin leak rate

M edium insulin leak rate
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Phase II

Low insu|in |eak rate

Phase III

Figure 60 Scheme of Immediate Impact theory

Large CPE-215® domains are not favored thermodynamically; entropy
causes CPE-215® to distribute evenly in the bilayers. When CPE-215® molecules
begin to diffuse out of the CPE-215® rich domain, the transport “pores” begin to
disappear, and the insulin release rate starts to decrease. This is what we call
Phase II in Figure 59 and 60.
When all the CPE-215® molecules in the domains are evenly distributed in
the lipid bilayers, no more “pores” exist and the release rate goes back to the
blank control leakage rate. W e define this mode as Phase III in Figure 59 and 60.
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This hypothesis implies that the CPE-215®-evenly-distributed liposomes
should have a similar leakage rate comparable to the blank control liposomes,
and should be able to be reactivated by CPE-215®/cottonseed oil droplets. In
order to test the validity of the theory, we designed a new release experiment.
Two kinds of liposomes were made, one was 4:1 (weight ratio) DPPC/cholesterol
liposome, and the other was DPPC/CPE-215®/cholesterol liposome. In the
DPPC/CPE-215®/cholesterol liposome, CPE-215® was evenly distributed in the
lipid bilayers, DPPC/CPE-215® molar ratio was 2:1 (weight ratio 6:1), and
DPPC/cholesterol weight ratio was still 4:1. According to our theory and the
release data of Figure 59, after 6 hours, CPE-215® should be evenly distributed
in the lipid bilayers; if another dose of formulation was added then, there should
be another enhanced insulin release rate. In this set of experiments, there were
five release tubes, two of them were used for controlling the leakage rate of
DPPC/cholesterol liposome and DPPC/CPE-215®/cholesterol liposome, two of
them were used to see the enhanced release effect of adding oil mixture into
DPPC/cholesterol liposome and DPPC/CPE-215®/cholesterol liposome at time
zero, the last one was subjected to a second oil mixture “injection” after 6 hours
to see if there would be renewed release boost.
Figure 61 shows the insulin release results of this set of experiments and
Figure 62 is a close-up of Figure 61 at early times. The leakage rate of
DPPC/CPE-215®/cholesterol liposome was similar to that of DPPC/cholesterol
liposome, sometimes even slower than that of DPPC/cholesterol liposome, which
is in good agreement with our hypothesis theory. Although the third point of the
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DPPC/cholesterol liposome release curve was a little low, it was still within the
experimental error. Release from the DPPC/CPE-215®/cholesterol liposomes
was activated by CPE-215®/cottonseed oil mixture, similar to what CPE215®/cottonseed oil mixture did to DPPC/cholesterol liposome. Again this agrees
with our theory. W e think that evenly distributed CPE-215® has a function similar
to cholesterol in membrane barrier. In DPPC/CPE-215®/cholesterol liposome,
there was already a large amount of CPE-215® evenly distributed in the lipid
bilayers, the impact by outside oil mixture should not be as significant as in
DPPC/cholesterol liposome, and the “pore” disappearing process should be
slower due to reduced driving forces, which explained why in Figure 61 the
“DPPC/CPE/Chol C&C” curve had a lower slope than the “DPPC/Chol C&C”
curve at the beginning and took longer time to go back to the control leakage
rate. The “DPPC/Chol 2C&C" curve showed another boost after a second
addition of oil mixture at Hour 6 , which is a very strong argument for our theory.
All in all, this set of experiment proves the validity of our hypothesis on the
membrane permeation enhancing effect of CPE-215®.
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Figure 61 Insulin release at 37°C from different liposomes.

Note that the “DPPC/Chol 2C&C” and “DPPC/Chol C&C” samples were
having the exact same condition during the first 6 hours, so their release data in
the first 6 hours should be the same, and they ARE the same in Figure 61, which
shows the reproducibility of our experimental technique and sample handling.
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Figure 62 Close-up of Figure 61 at early times.

An important implication of this permeation mechanism is that CPE-215®
is a SAFE membrane permeation enhancer. There are many kinds of membrane
permeation enhancers out in the market. Some of these enhancers cause
irritations, but what patients and the FDA are concerned most with is whether
they are safe to use, whether they destroy the integrity of the membranes and let
everything flow into the human body at the same time as the drug is delivered.
Based on our theory, CPE-215® can only form transient “pores” in the membrane
for a short period of time, and then the barrier function of the membrane is re
established. In our in vitro study, the time from “pore” formation to “pore"
resorption was about 6 hours; while in human body, cell metabolism is carried
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out at all times, so the in vivo time from “pore” formation to “pore” resorption
should be less than 6 hours, which makes CPE-215® safer to use than other
membrane permeation enhancers.
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CHAPTER 5
QUANTITATIVE RELEASE MODEL

We have proposed a theory to describe the process of protein release
from liposomes and carried out a set of testing experiments to prove the validity
of this theory. In this chapter we developed a mathematical model based on this
theory to quantify the release results. A semi-empirical nonlinear equation
involving four parameters effectively fits the protein release profiles. Finally we
used a neural network approach to correlate the different release condition
parameters and the four semi-empirical fitting parameters based on our limited
data sets.

5.1. Mathematical Model
Based on our theory, the whole release process is simplified to be the
combination of two steps: at the beginning it is the boost release triggered by the
permeation enhancers; after the permeation enhancers are evenly distributed
inside of the lipid bilayer, it is the self-leakage of liposome.
The part of the triggered boost release can be empirically expressed as a
simple linear time dependent event
[5.1]

y = a -t + b
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where

y

is the percentage of protein released from liposome, a is the boost

release rate, b represents the systematic error of the experiment (theoretically, b
should be zero, but due to the temperature change at time zero and the sample
processing time between taking the sample and finishing the separation of
protein and liposome, b is always a little bit more than zero).
The self-leakage of liposomes can also be empirically expressed as a
simple linear time dependent event
y = c

•t +

where

y

[5.2]

d

is the percentage of protein released from liposome, c is the liposome

self-leakage rate.
We introduced another parameter, t*, which is the transition time between
the triggered boost release and the self-leakage of liposomes
where

a -t*+ b = c -t*+ d

[5 .3]

then d

-

[5.4]

( a - c ) - t* + b

and the self-leakage of liposome can be expressed as
[5.5]

y = c-t + ( a - c ) - t* + b

Mathematically, we combined both release steps [5.1] and [5.2] through
the following equation
1

y =

1
a -t + b

1

[5.6]

c-t + ( a - c )-t*+ b

or alternatively

164

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

which could smoothly link the two release steps and represent the whole release
process. Practically Equation 5.7 is a better fit than Equation 5.6 to all
experimental data. Equation 5.7 was used to express the whole release process.
We used the “Solver” function of Excel® to estimate the best

a , b, c

and

t*

values to make the Equation 5.7 fit the experimental data through a least square
non-linear curve fit. Figure 63 is an example of the fitting. The complete fitting
results for all release curves can be found in Appendix.
The experimental data used in Figure 63 are from the “CPE215” sample in
Chapter 3.2.2, shown as square dots. The lines of

“a t+ b ”

and “cf+aT are shown in

blue and pink colors respectively, and the t* value can be found in the cross point
of these two lines.
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Figure 63 Modeling curves and the experimental release data of the
“CPE215” sample in Chapter 3.2.2. The blue line is the " a t + b ” , which
represents the boost release; the pink line is “ c t + d ” , which represents the
later self-leakage of liposome. The time value of the cross point of the two
lines is t*. The experimental data points are shown as square dots.

Equation 5.7 was used as the modeling equation for all the release
experiments, and a,

b , c, t *

were obtained from the Excel® “Solver” function

within reasonable range to generate the best fits. Most modeling curves fit well
with the experimental data, which, to some extent, contributes to the validity of
our theory. With the values of a,

b , c , t*,

we can generate the whole release

profile. Table 8 shows the fitting results with Equation 5.7.
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50

Table 8 Modeling parameters for the release experiments.
Chapter #
3.2.2
3.2.2
3.3.1
3.3.1
3.3.1
3.3.1
3.3.2
3.3.2
3.3.2
3.3.3
3.3.3
3.3.3
3.3.3
3.4.1
3.4.1
3.4.1
3.4.1
3.4.1
3.4.2
3.4.2
3.4.2
3.4.2
3.4.2
3.4.2
3.5.1
3.5.1
3.5.2
3.5.2
3.5.2
3.5.3
3.5.3
3.5.3
3.6
3.6
3.6

Sample
Blank
CPE215
B-CD
CPE&CSO
B-CD+CPE&CSO
a-CD+CPE&CSO
C&C+20X B-CD
C&C+1x a-CD
C&C+20x a-CD
Blank
CSO+B-CD
CPE+B-CD
CPE+CSO+B-CD
Blank
CPE-215
Cottonseed Oil
CPE+B-CD
CSO+B-CD
Blank
B-CD
1xCPE&CSO
3xCPE&CSO
1xCPE&CSO+B-CD
3xCPE&CSO+B-CD
pH7 Blank
pH7 C&C+B-CD
Blank
C&C
C&C+B-CD
Blank
C&C
C&C+B-CD
Blank
CPE
CPE&CSO

a (%»hour'1)
1.66
3.29
4.14
6.72
10.65
15.25
14.68
9.94
14.08
0.71
11.83
6.57
11.87
0.90
2.90
4.26
4.90
7.11
0.91
4.17
8.58
10.20
23.96
29.26
0.66
20.62
0.32
1.16
5.02
0.36
0.46
4.16
1.32
2.10
4.13

b (%)
10.41
3.43
12.93
8.68
9.02
23.07
16.79
9.86
10.43
49.44
55.55
51.72
40.41
2.14
0.41
0.65
1.34
1.67
4.02
5.59
3.21
5.11
9.34
13.66
-0.07
-2.33
-0.14
-1.91
-2.33
-0.73
-0.37
2.15
0.29
-0.81
-2.36

c (%*hour'1)
0.48
0.42
0.15
0.19
0.33
0.09
0.23
0.20
0.19
0.20
0.02
0.16
0.28
0.70
0.62
0.30
0.58
0.83
0.71
0.50
0.45
0.20
0.39
0.54
0.62
0.70
0.36
0.89
0.79
0.23
0.20
1.30
0.40
0.50
0.23

t* (hour)
6.79
6.01
5.32
3.54
2.20
3.47
2.12
2.51
1.94
10.00
1.00
0.65
0.94
10.00
2.60
5.78
6.47
5.14
54.29
5.01
4.04
4.22
2.35
1.63
2.45
2.53
21.75
9.04
14.09
16.91
23.42
7.87
49.04
29.68
18.83

One can observe that the a value, representing the burst release rate, is
system dependant and fluctuates widely based on the release conditions from
0.32 %/hour to almost 30 %/hour. The c value reflects the leakage rate and
should be small and reasonably the same for all systems; in our case, it ranges
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from 0.02 %/hour to 1.3 %/hour. Here, c < a. Although

t*

has a physical meaning

in the model, which is system dependant and related to the time needed for the
liposomes to restore the barrier function, it is hard to find a reasonable
explanation to the wild fluctuation of
meaning of

t*

t*

values given by the model in Table 8. The

in the model may need further modification.

5.2. Neural Network

5.2.1. Introduction to Neural Network
A neural network is an information processing paradigm that is inspired by
the way biological nervous systems, such as the brain, process information.127
The key element of this paradigm is the novel structure of the information
processing system. It is composed of a large number of highly interconnected
processing elements (neurons) working in parallel to solve specific problems.
Neural networks, like people, learn by example. A neural network is configured
for a specific application, such as pattern recognition or data classification,
through a learning process. Learning in biological systems involves adjustments
to the synaptic connections that exist between the neurons, which is true for
neural networks as well.
The field of neural network was established before the advent of
computers, but many important advances did not appear until the use of fast and
inexpensive computers.
Neural networks take a different approach to problem solving than that of
conventional computers. Conventional computers use an algorithmic approach,
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i.e. the computer follows a set of instructions in order to solve a problem. Unless
the specific steps that the computer needs to follow are known, the computer
cannot solve the problem. But computers would be so much more useful if they
could do things that we don't exactly know how to do. Neural networks process
information in a similar way the human brain does. They cannot be programmed
to perform a specific task. The examples must be selected carefully otherwise
useful time is wasted or even worse the network might be functioning incorrectly.
The disadvantage is that because the network finds out how to solve the problem
by itself, its operation can be unpredictable.
An artificial neuron (Figure 64) is a device with many inputs and one
output. The neuron has two modes of operation; the training mode and the
predictive mode. In the training mode, the neuron can be trained to fire (or not),
for particular input patterns. In the predictive mode, when a taught input pattern is
detected at the input, its associated output becomes the current output.

XI

TEACH/USE

X2

INPUTS

Neuron

»

OUTPUT

Xn
TEACHING INPUT

Figure 64 A simple artificial neuron in Neural Network.
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The most common type of artificial neural network consists of three layers
of neurons: a layer of "input" elements is connected to a layer of "hidden"
neurons, which is connected to a layer of "output" neurons (Figure 65). The
activity of the input units represents the raw information that is fed into the
network. The activity of each hidden unit is determined by the activities of the
input units and the weights on the connections between the input and the hidden
units. The behavior of the output units depends on the activity of the hidden units
and the weights between the hidden and output units.

Hidden layer

Outputs

Figure 65 An example of a fully connected feed-forward network.

Every neural network possesses knowledge which is contained in the
values of the connections weights (Figure 66). Modifying the knowledge stored in
the network as a function of experience implies a learning (training) rule for
changing the values of the weights. Information is stored in the weight matrix
of a neural network. Learning (training) is the determination of the weights.
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W

Output activation (Ay) multiplied
by individual connection weights
(Wjk) sent to other neurons

Incoming neural activations (A,)
multiplied by individual
connection weights (W jj)

I» 'r
. 1=1

Figure 66 Activation (output) of Neuron j, Aj. W is the individual
connection weight; 0j is the offset or threshold.

Since neural networks are best at identifying patterns or trends in data,
they are well suited for prediction or forecasting needs including sales
forecasting, industrial process control, customer research, data validation, risk
management, target marketing, etc. The ability to learn by example makes neural
network very flexible and powerful. Furthermore, there is no need to devise an
algorithm in order to perform a specific task; i.e. there is no need to understand
the internal mechanisms of that task.
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5.2.2. Application of Neural Network Model
One major purpose of modeling is to have the ability to forecast. Although
we have proposed a theory and mathematical model for the process of protein
release from liposomes with permeation enhancers, we would like to use a
neural network to predict the release process, i.e. to predict a,

b , c, t*

values,

based on given conditions.
There are nine major factors that affect the protein release profile, which
means there are nine inputs for our neural network. These inputs are AT (T-Tc),
cholesterol content in lipid bilayer, molecular weight of protein, amount of CPE215®, amount of cottonseed oil, ratio of total oil (CPE-215® and cottonseed oil) to
lipid content (DPPC and cholesterol), percent of (3-cyclodextrin in the aqueous
phase, percent of a-cyclodextrin in the aqueous phase, and pH.
We listed all nine factors and

a, b, c, t *

values for each experimental

release curve in Table 9. In order to easily trace back to the experiment, the
number of chapter where the experiment was mentioned in this thesis and the
sample name were also shown in Table 9. According to our liposome DSC data,
the phase transition temperature for 4:1 (w/w) DPPC/Cholesterol liposome is 46
°C, which is the reason why when using DPPC/Cholesterol liposomes at 37 °C,
the AT is shown as -9. We used insulin dimer for the insulin molecular weight
because we know at the release concentration and condition inside of liposomes,
insulin mostly existed as dimers, and probably penetrated the liposomes as
dimers. Since Table 9 was used for the training of our neural network, two sets of
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data (randomly selected), which were used to test the prediction, are not listed
here.

Table 9 Neural network matrix
Chap
#
3.2.2
3.2.2
3.2.2
3.3.1
3.3.1
3.3.1
3.3.2
3.3.2
3.3.2
3.3.3
3.3.3
3.3.3
3.3.3
3.4.1
3.4.1
3.4.1
3.4.1

Sample
Blank
CPE215
3-CD
CPE&CSO
6-CD+CPE&CSO
a-CD+CPE&CSO
C&C+20X 3-CD
C&C+1x a-CD
C&C+20x a-CD
Blank
CS0+3-CD
CPE+3-CD
CPE+CSO+3-CD
Blank
CPE-215
Cottonseed Oil
CPE+3-CD

3.4.2
3.4.2
3.4.2
3.4.2
3.4.2
3.4.2
3.5.1
3.5.2
3.5.2
3.5.2
3.5.3
3.5.3
3.5.3
3.6
3.6
3.6

Blank
3-CD
1xCPE&CSO
3xCPE&CSO
1XCPE&CSO+3-CD
3xCPE&CSO+3-CD
pH7 Blank
Blank
C&C
C&C+3-CD
Blank
C&C
C&C+3-CD
Blank
CPE
CPE&CSO

AT
(C)
0
0
0
0
0
0
0
0
0
0
0
0
0
-9
-9
-9
-9

Ch
(%)
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
20
20

Mw
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600

-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9
-9

20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20

11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
11600
66000
66000
66000

CPE215®
(9)

P-

0
0.25
0
0.258
0.258
0.258
0.046
0.046
0.046
0
0
0.0095
0.0095
0
0.0084
0
0.0084

oil: lipid
(w/w)
0
40.9
0
54.5
54.5
54.5
8.7
8.7
8.7
0
0.6
1.6
2.2
0
1
1.1
1

0
0
0
0.086
0.086
0.086
0.015
0.015
0.015
0
0.0032
0
0.0032
0
0
0.0096
0

CD
(%)
0
0
0.3
0
0.3
0
1
0
0
0
1
1
1
0
0
0
1.3

0
0
0.009
0.027
0.009
0.027
0
0
0.0084
0.0084
0
0.0084
0.0084
0
0.013
0.013

0
0
1.4
4.1
1.4
4.1
0
0
1.3
1.3
0
1.3
1.3
0
1
1.4

0
0
0.003
0.009
0.003
0.009
0
0
0.0028
0.0028
0
0.0028
0.0028
0
0
0.0043

0
1.7
0
0
1.7
1.7
0
0
0
1.7
0
0
1.7
0
0
0

cso
(g)

c
(%-h
b (%)
10.41
3.43
12.93
8.68
9.02
23.07
16.79
9.86
10.43
49.44
55.55
51.72
40.41
2.14
0.41
0.65
1.34

O

0
0
0
0
0
2.1
0
0.05
0.9
0
0
0
0
0
0
0
0

pH
7.4
7.4
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7

a
(%*hr
-1)
1.66
3.29
4.14
6.72
10.65
15.25
14.68
9.94
14.08
0.71
11.83
6.57
11.87
0.90
2.90
4.26
4.90

0.48
0.42
0.15
0.19
0.33
0.09
0.23
0.20
0.19
0.20
0.02
0.16
0.28
0.70
0.62
0.30
0.58

t*
(hour)
6.79
6.01
5.32
3.54
2.20
3.47
2.12
2.51
1.94
10.00
1.00
0.65
0.94
10.00
2.60
5.78
6.47

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

7
7
7
7
7
7
7
10
10
10
4
4
4
7
7
7

0.91
4.17
8.58
10.20
23.96
29.26
0.66
0.32
1.16
5.02
0.36
0.46
4.16
1.32
2.10
4.13

4.02
5.59
3.21
5.11
9.34
13.66
-0.07
-0.14
-1.91
-2.33
-0.73
-0.37
2.15
0.29
-0.81
-2.36

0.71
0.50
0.45
0.20
0.39
0.54
0.62
0.36
0.89
0.79
0.23
0.20
1.30
0.40
0.50
0.23

54.29
5.01
4.04
4.22
2.35
1.63
2.45
21.75
9.04
14.09
16.91
23.42
7.87
49.04
29.68
18.83

aCD
(%)

The neural network software we are using is FORECASTER XL™ from
ALYUDA Research, Inc, which is a MS Excel add-in program for forecasting and
data analysis using neural network method. We used this program to form the
network and forecast

a , b , c, t *

values one at a time. In that case, we have nine
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inputs and one output each time. We have 33 sets of data to form the network, in
which 85% (28) of the data sets would be used for network training and 15% (5)
of the data sets would be used for testing purposes by the program; the program
requires the data sets should be at least three times more than the number of
inputs, and we barely met this minimum requirement.

5.2.3. Neural Network Model Analysis
For neural network modeling, the major task for users is to form the input
and output matrix, then the rest is all automatic calculation. W e did the
calculation for

a, b, c

and

t*

one by one. After each calculation, the program gave

a report on the neural network formed.
For the network formed for the purpose of predicting the value of a, the
program gave some figures to visualize the deviation of the forecasted value
from the actual result. From Figure 67, we can see the forecasted value did not
deviate from the actual value significantly, except for a few rows. Given the
limited number of experimental data sets, this is a reasonable network model for
the prediction the value of a.
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Figure 67 The actual vs. forecast for the neural network for predicting a.
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16.901%
4.683%
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2.232%
1.907%

D6
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Figure 68 Input importance for each parameter in the network for
predicting a. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer,
E6 is the molecular weight of protein, F6 is the amount of CPE-215®, H6
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of
(3-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in
the aqueous phase, and K6 is pH.
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Figure 68 shows that the parameters of temperature, cholesterol content
in lipid bilayer, (B-cyclodextrin concentration and pH have significant influence on
the a value, which is the rate of triggered boost release at the beginning of the
protein release. Based on our knowledge of our protein release system, the
major factors that the network picked seem reasonable: the temperature and
cholesterol content have significant influence on liposome properties; (3cyclodextrin is an efficient phase transfer agent to transport CPE-215® to the
membrane; pH would affect the surface charge character of proteins and as a
result greatly alter the permeation ability of proteins.
For the neural network formed for the purpose of predicting the value of c,
the program also gave some figures to visualize the deviation of the forecasted
value from the actual result. From Figure 69, we can see the forecasted value did
not deviate from the actual value too much. Again, this is a reasonable network
model for the prediction of c value.
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Figure 69 The actual vs. forecast (scatter plot) for the neural network for
predicting c.
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Figure 70 Input importance for each parameter in the network for
predicting c. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer,
E6 is the molecular weight of protein, F6 is the amount of CPE-215®, H6
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of
P-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in
the aqueous phase, and K6 is pH.
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Figure 70 shows that temperature, cholesterol content in lipid bilayer, (3cyclodextrin concentration and pH have significant influence on the c value,
which is similar to what the previous neural network picked for a value. The value
of c represents the self-leakage rate of liposomes. Again, this is a reasonable
pick of major parameters for the similar reasons.
For the neural network formed for the purpose of predicting the value of
the program also gave some figures to visualize the deviation of the forecasted
value from the actual result. The value of

t*

represents the time when the

permeation enhancers starts to diffuse evenly within the lipid bilayer and the
system starts to change from the triggered boost release to liposome self
leakage. From Figure 71, we can see the forecasted value did not deviate from
the actual value too much, except for one and actually that one is a “Blank”
sample. As to “Blank” samples, f*does not have meanings for them, because
they actually do not have a transition time point. Therefore, this is an effective
network model for the prediction of

t*

value for non-“Blank” samples.
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t*,
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40.6491

— Actual
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■
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Figure 71 The actual vs. forecast (scatter plot) for the neural network for
predicting

t*.

19.231%

0 .000%
2.115%
0.443%
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27.097%
20.546%
20.883%
40%
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Figure 72 Input importance for each parameter in the network for
predicting t*. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer,
E6 is the m olecular w eight of protein, F6 is the a m ount o f CPE-215®, H6
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of
(3-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in
the aqueous phase, and K6 is pH.
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Figure 72 shows that temperature, cholesterol content in lipid bilayer,
protein molecular weight and pH have significant influence on the

t*

value. It is

easy to understand the influence of temperature and cholesterol content in lipid
bilayer on the

t*

value, but it is hard to relate t* to protein molecular weight and

pH. Maybe this is due to the limitation in the number of data sets.
Neural network training was performed for
as expected. The parameter

b

b

= 0 .01, since the

b

but the result was not useful

has the meaning of systemic error; therefore,

there is no real meaning in predicting
used

b,

b

value. For the purpose of forecasting, we

value can not be zero.

5.2.4. Neural Network Prediction
After we formed the neural networks for a, c and

t* ,

we wanted to see if

the neural networks can predict reasonable values for a, c and

t*

for other

release experiments. Table 10 shows the data sets we used to test the neural
network prediction. Table 11 gives out the result of neural network prediction
values versus the mathematical fit values of a ,

c

and

t*.

Table 10 Experimental data sets for neural network prediction.
Chap
#
3.4.1
3.5.1

AT
Sample
CSO+B-CD
C&C+B-CD

(C)
-9
-9

Choi
(%)
20
20

CPE215®
Mw
11600
11600

(9)
0
0.009

oil:
lipid
(w/w)

1.1
1.4

PCSO

(g)
0.0096
0.003

CD
(%)
1.3

1.7

aCD
(%)
0
0
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pH

7
7

Table 11 Neural network prediction compared with the math model result.
CSO+B-CD
C& C+B-CD
Math Fit
Neural Network
Math Fit
Neural Network
Prediction
Prediction
a (% 'hour'1)
7.11
7.88
20.61
24.03
b(% )
1.67
0 .01T
-2.33
0 .01T
c (%‘ h o u r1)
0.83
0.68
0.54
0.70
t * (hour)
5.14
2.39
2.53
2.07
t The value ol b in Neural Network is not pred icted, but arbitrarily put as 0.01

Figure 73 and Figure 74 show the deviation of the forecasted model curve
from the real experimental data. One neural network prediction fits well with the
experimental data, while the other only fits the early data. Given the fact that the
neural network forecast was based on

a,

c, and

t*

values that were from the

empirical mathematical model, which was not exactly the same as the real data,
and the limited number of data sets, the prediction are acceptable, though we
recognize that they are far from ideal.
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Figure 73 Neural network forecast for “CSO+B-CD” sample in Chapter
3.4.1.
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Figure 74 Neural network forecast for “C&C+B-CD” sample in Chapter
3.5.1.

Among the three major parameters a, c, and

t*, a

is the one that we are

most interested in to do predictions since it is the triggered boost release rate.
Based on the neural network we formed, we wanted to know under what
conditions the highest a value could be achieved. Figure 68 shows the individual
connection weight for each input condition — temperature, cholesterol content in
lipid bilayer, (3-cyclodextrin concentration and pH have significant influence on
the a value. The neural network predicted the maximum a value could be
reached at 37 °C in pH 7 from 4:1 DPPC/Cholesterol liposome with the highest
concentrations of phase transfer agents, CPE-215® and cottonseed oil. In
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practical situations, phase transfer agents have their solubility limit and the
amount of CPE-215® and cottonseed oil added does have limit. Under the
conditions of 37 °C, pH 7, 4:1 DPPC/Cholesterol liposome, insulin dimer, 0.06 g
CPE-215®, 0.02 g cottonseed oil, 1.7% P-cyclodextrin, 2.1% a-cyclodextrin, the
neural network predicted the boost release rate, a value, to be 31.9 %*hour"1,
which is more than 40 times faster than the liposome leakage rate (0.73 %*hour'
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CHAPTER 6

CONCLUSION

In our study of the enhancement effect of cyclopentadecanolide (CPE215®) on protein permeation through lipid membranes, we successfully designed
and developed a novel in vitro membrane permeability model - liposome. This
model system can not only be used to perform in vitro protein release
experiments, but also can be used as a tool to select promising intranasal
formulations before the expensive animal tests. W e effectively labeled the
proteins (insulin and BSA) with fluorescein to increase their detection sensitivity
at low concentrations. By utilizing the extrusion technique, we can prepare
“mono-dispersed” 400 nm large unilamellar vesicles/liposomes; when using 1%
(weight) lipid content to make 400 nm unilamellar DPPC liposomes, the
encapsulation efficiency is 10%. We prepared different liposomes with DPPC,
cholesterol and CPE-215®, among which DPPC was the major lipid component.
We utilized liposomes to encapsulate fluorescein labeled insulin, fluorescein
labeled BSA and calcein. We used the centrifugal extraction method to clean the
unencapsulated molecules and the molecules adsorbed on the outside surface of
liposomes, so that the fluorescence signal outside of liposome was close to the
background signal of the buffer solution. W e utilized this model to perform a

185

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

series of protein release kinetics experiments from liposomes at 37 °C, 42 °C, at
pH 7, pH 4, pH 10, in the presence of CPE-215®, cottonseed oil, cyclodextrins.
The experimental results show that CPE-215® is an effective membrane
permeation enhancer for proteins; because of the limited solubility of hydrophobic
CPE-215® in water, a phase transfer agent, for example, cyclodextrins, can
further enhance the permeation effect of CPE-215®. The pH of the solution has a
huge impact on the protein release profile due to the protein surface charge
change caused by the pH change. Proteins permeate through lipid bilayers
easier at pH levels around its isoelectric point.
Studies on insulin solution properties (self-diffusion and self-association
states), the interaction between insulin and liposome, and the interaction
between CPE-215® and liposomes were carried out to understand the
mechanism behind the fact that CPE-215® facilitates the protein transport
through lipid bilayers. W e determined insulin diffusion coefficient at pH 3 at 37 °C
to be 1.4 x 10' 10 m2/s, or 1.4 x 10'6 cm2/s by the pulsed field gradient NMR
technique. W e determined the binding constant of insulin on a DPPC/Cholesterol
liposome surface to be

K

= 97 ml/mg, which indicates that insulin only has weak

interactions with liposomes. However, we identified that CPE-215® almost
doubled the insulin adsorption energy on liposome surface by ITC. Based on our
calculation, there would be 20 insulin dimers adsorbed on the inner surface of
each 400 nm liposome in our release conditions. By modulated DSC, we
determined that CPE-215® could diffuse across the aqueous phase into the
bilayer through limited number of thermal cycles from 10 °C to 90 °C; 20%
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(weight) CPE-215® can broaden the Tc range, lower the Tc of DPPC liposome by
8 °C and the Tc of DPPC/Cholesterol liposome by 9 °C, and reduce the AH of
DPPC transition from 37 kJ/mol to 20 kJ/mol.
Based on the mechanism study, our release data and the current
liposome leakage theory, we proposed a hypothesis that CPE-215® would form a
transient “pore” in the lipid bilayer at the beginning of the release experiment;
after CPE-215® evenly diffused within the bilayer, the barrier function of the lipid
bilayer was restored. We performed one set of testing experiments and the result
supported our hypothesis theory.
Mathematical modeling approach was used based on our theory. The
release kinetics was modeled with Equation 5.7,
1

v( a •t +

b)2

(c-t + ( a - c ) - t * + b

)2,

where y is the percentage of protein released from liposome, a, c,
adjustable parameters: a is the boost release rate,

b

t*

are

represents the systemic

error of the experiment, c is the liposome self-leakage rate,

t*

is the transition

time between the triggered boost release and the self-leakage of liposomes.
Most release data fit well with this model, which further supported our hypothesis
theory.
We used the neural network approach to find the internal connections
between different release condition parameters based on our limited data sets
and tried to predict the protein release profile at new conditions. The values of a,
c, f*w ere correlated to experimental conditions (temperature difference between
187
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the release temperature and the phase transition temperature of liposome, the
cholesterol content in the liposome, the protein molecular weight, the amount of
CPE-215®, the amount of cottonseed oil, the weight ratio of oil (CPE-215® and
cottonseed oil) to lipid (DPPC and cholesterol), the amount of p-cyclodextrin and
a-cyclodextrin, and pH) through neural networks. Neural network predicted the
values of a and

c

within 20% error, and

t*

with a 20% to 50% error. The initial

boost release rate is the most concerned parameter when the model is used to
determine the promising intranasal formulations. The prediction result shows that
reasonable neural networks were successfully formed for the major parameters
of the mathematical model. The neural network predicted the maximum value of
a of 31.9 %»hour'1, for the condition of 37 °C, 4:1 DPPC/Cholesterol liposome at
pH 7 with 1.7% of P-cyclodextrin and 2.1 % a-cyclodextrin, 0.06 g CPE-215® and
0.02 g cottonseed oil, which is more than 40 times faster than the liposome
leakage rate.
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APPENDIX

In Chapter 5.1, we developed a mathematical model, based on our theory
of protein release from liposomes, to quantify the release results. Equation 5.7
was used as the modeling equation to express the whole protein release process.
1
[5.7]

We used the “Solver” function of Excel® to estimate the best a, b , c and t *
values to make the Equation 5.7 fit the experimental data through a least square
non-linear curve fit. Table 6 listed the result of the curving fitting. The figures in
the Appendix show the detail curve fitting for each release curve: the diamond
dots are the experimental data points and the line is the fitting curve. The R2
value was also given by
n

R 2 = \~ —

n

where y. is the experimental protein percent release value, y. is the predicted
percent release value, y is the mean.
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